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ABSTRACT OF DISSERTATION 
LEPTIN RESISTANCE INDUCED OBESITY AND DIABETES 
PROMOTE NEUROPATHOLOGICAL CHANGES IN THE AGING BRAIN 
The aging brain is prone to the development of pathology and dementia.  With a 
rapidly growing elderly population diagnoses of neurodegenerative diseases, such as 
Alzheimer’s disease (AD), frontotemporal dementia (FTD), and Parkinson’s disease are 
on the rise. Additionally, diabetes and obesity are linked to an increased risk of dementia. 
The convergence of this increasingly aged population with the obesity and diabetes 
epidemic give rise to new concerns regarding the future of prevention and treatment of 
neurodegenerative diseases. Our lab has previously shown that leptin, an adipokine 
involved in signaling satiety to the hypothalamus, can modulate the generation of the 
amyloid beta (Aβ) peptide (a toxic peptide associated with neurologic disease) and 
attenuate hyperphosphorylation of the tau protein (another peptide prone to forming large 
insoluble structures causing neurodegeneration). From these studies we have elucidated 
that leptin resistant mice (which develop severe obesity and type-2 diabetes mellitus) 
with knock-in mutations for the amyloid precursor protein (APP) and presenilin-1 (PS1) 
genes develop extensive vascular pathology and cognitive impairments. Interestingly, 
these mice do not display increased levels of amyloid deposition in the brain. 
Additionally, increased tau phosphorylation occurs in these mice with leptin resistance. 
As a follow up to this study db mice were transduced, via adeno-associated virus, with 
the tau P301L mutant to induce the development of tangle pathology. These mice 
displayed no cognitive deficits, yet they displayed increases in both tau phosphorylation 
and tangle count within the hippocampus. Collectively, these studies indicate leptin 
resistance, obesity, and type-2 diabetes mellitus promote the development of 
cerebrovascular and neurofibrillary tangle pathologies associated with neurodegeneration 
and dementia. These observations open many previously unexplored avenues for 
developing novel therapeutics to treat these devastating diseases.  
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CHAPTER ONE: Introduction 
1.1 - Alzheimer’s Disease and Other Dementias 
1.1.1 - Alzheimer’s Disease Background 
The brain becomes more susceptible to neurologic disease as it ages. Factors 
which contribute to the development of these diseases are numerous; however, age is the 
number one driving factor. Alzheimer’s disease (AD), for example, is the most common 
neurodegenerative disease associated with age. Worldwide 36 million individuals have 
AD, a number which is expected to double in the next 20 years. The healthcare system 
already incurs huge financial costs due to AD, with over 200 billion dollars going 
towards treatment and care of individuals with the disease annually. If the projected 
estimates are correct, it will cost over 1.1 trillion dollars a year to care for these patients 
by 2050. This burden will cripple the healthcare system if no therapeutics are developed. 
Despite tremendous effort put toward understanding the mechanisms underlying the 
disease, there is still no cure for AD, and no effective treatments to stop the development 
of pathology. 
There are several clinical characteristics of AD, the most well-known being loss 
of memory and cognitive function. A variety of cognitive exams, such as the mini-mental 
state exam (MMSE) and the mini-cog exam, evaluate memory, temporal awareness, and 
basic cognitive skills. In addition to cognitive decline, patients tend to display behavioral 
changes, such as depression, agitation, difficulty sleeping, and delusions. Physicians are 
aware these changes occur and typically prescribe psychotropic drugs like 
antidepressants, anxiolytics, etc. In the final stages of AD patients begin losing their 
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ability to physically perform daily tasks or to care for themselves and ultimately spend 
their last few months bedridden. Despite these hallmark symptoms a clinical diagnosis of 
AD currently can’t be made until autopsy by identifying the key pathological hallmarks 
of the disease: amyloid plaques (comprised of the Aβ peptide) and neurofibrillary tangles 
(NFTs) made from hyperphosphorylated tau protein.  
1.1.2 – Mechanisms of Amyloid Pathogenesis 
The Aβ peptide is formed when APP (a membrane protein with 4 isoforms 
ranging from 695 to 770 amino acids in length) (Sandbrink, Masters et al. 1996), is 
cleaved by two enzymatic activities. Under non-amyloidogenic conditions, α-secretase 
cleaves APP within the Aβ region, followed by γ-secretase cleavage, producing the APP 
intracellular domain (AICD), the soluble APP fragment α (sAPPα), and the p3 fragment 
(Selkoe 2001). In the amyloidogenic pathway APP is first cleaved by β-secretase. This is 
again followed by γ-secretase cleavage, releasing the AICD, sAPPβ, and the Aβ peptide 
(Fig. 1.1) (Chen, Hasegawa et al. 2006). Aβ peptides are 36–43 amino acids long, the 
most common being Aβ40, which represents about 80% of the total pool. A less common 
(10%) form of the peptide, Aβ42, is considered to be more pathogenic, having a high 
tendency to aggregate (Tanzi and Bertram 2005, Karran, Mercken et al. 2011). 
Aggregation creates oligomers, fibrils, filaments, and ultimately, plaques (Ohnishi and 
Takano 2004). These plaques form in the cortex and hippocampus (Robinson, Geser et al. 
2011). Neuritic plaques are surrounded by dystrophic neurites and activated glia (Hu and 
Van Eldik 1999), and are likely an ongoing source of neuroinflammation (Griffin, Sheng 
et al. 1998, Meda, Baron et al. 2001). Although plaques are directly connected to the 
3 
disease process, recent evidence suggests that diffusible Aβ oligomers may play a greater 
role in driving neurodegeneration than plaques (Demuro, Mina et al. 2005, Glabe 2006). 
Under normal conditions, ~90% of APP processing is performed within the non-
amyloidogenic pathway and ~10% by the amyloidogenic pathway (Ahmed, Holler et al. 
2010). It is not known what causes the shift to increased APP processing by the 
amyloidogenic pathway in AD (Fukumoto, Cheung et al. 2002). One hypothesis suggests 
that increased cholesterol levels result in lipid raft formation, which has been suggested 
to be the physiological site of β-secretase and γ-secretase activity (Korade and 
Kenworthy 2008, Rushworth and Hooper 2010, Evangelisti, Wright et al. 2013). β-
secretase cleavage is the rate-limiting step in Aβ generation, and β-secretase activity 
levels are thought to increase throughout the progression of AD (Ahmed, Holler et al. 
2010, Holler, Webb et al. 2012). In other cases, mutations in APP and processing 
enzymes (APP, PS1, PS2); which are typical in cases of familial AD (FAD), can enhance 
Aβ generation by increasing available substrate and promote amyloidogenic cleavage of 
APP (Corder, Saunders et al. 1993, Sherrington, Rogaev et al. 1995, Jankowsky, Fadale 
et al. 2004). Other findings point to a decrease in Aβ clearance from the brain, resulting 
in a gradual accumulation during aging (Tanzi, Moir et al. 2004). 
1.1.3 - Tau Pathogenesis 
It is likely that a major portion of the neurodegeneration observed in AD and 
other tauopathies, diseases involving the pathological aggregation of the tau protein, 
results from tau pathology. For example, the number of NFTs correlates with clinical 
disease severity (Arriagada, Marzloff et al. 1992, Gomez-Isla, Hollister et al. 1997). The 
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amyloid cascade hypothesis suggests the series of pathologic events observed in AD are 
driven by amyloid pathology (Hardy and Allsop 1991, Gotz, Chen et al. 2001, Lewis, 
Dickson et al. 2001, Oddo, Caccamo et al. 2003, Ittner and Gotz 2011). As a result, the 
equilibrium of tau phosphorylation and dephosphorylation is altered, ultimately leading 
to tangle formation, neuronal dysfunction, and cell death (Hardy and Allsop 1991, 
Karran, Mercken et al. 2011, Lambert and Amouyel 2011) (Fig. 1.2).  
Tau is a microtubule-stabilizing protein present in the cytoplasm of axons but 
generally absent in the dendrites (Maas, Eidenmuller et al. 2000). Tau acts on tubulin to 
promote polymerization of the microtubule, paving the way for axonal transport 
(Weingarten, Lockwood et al. 1975). The MAPT gene, which encodes the tau protein, 
resides on chromosome 17 and is comprised of 16 exons (Duff, Knight et al. 2000). 
MAPT has four domains: N-terminal, C-terminal, microtubule binding domain (MBD), 
and a proline-rich domain (Mandelkow, Schweers et al. 1996, Ballatore, Lee et al. 2007). 
The N-terminal and MBD regions are alternatively spliced to include or exclude exons 2, 
3 and 10, resulting in 6 possible isoforms of the tau protein (Deshpande, Win et al. 2008). 
The resulting isoforms contain either 3 or 4 microtubule binding domains (3R and 4R 
respectively) and contain 0, 1 or 2 N-terminal domains (0N, 1N or 2N respectively) 
separated by a proline rich domain (Forman, Lee et al. 2000). MAPT also contains two 
haplogroups, H1 and H2, where increased H1 levels correlate with an increased risk of 
tauopathy (Forman, Lee et al. 2000). The tau protein undergoes a variety of post-
translational modifications (Hasegawa, Morishima-Kawashima et al. 1992, Watanabe, 
Takio et al. 1999, Morris, Maeda et al. 2011), including cross-linking (Chau, Radeke et 
al. 1998), glycosylation (Robertson, Moya et al. 2004), nitration (Reynolds, Reyes et al. 
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2006), and phosphorylation (Morishima-Kawashima, Hasegawa et al. 1995). The large 
number of post-translational modifications of tau suggests that tau is highly-regulated by 
complex pathways. The primary cause of tau dysfunction is due to phosphorylation of tau 
by enzymes such as GSK3β (Michel, Mercken et al. 1998), AKT (Ksiezak-Reding, Pyo 
et al. 2003), or CDK5 (Lund, McKenna et al. 2001), along with many other kinases 
(Forman, Lee et al. 2000, Martin, Latypova et al. 2013). Phosphorylation of tau occurs at 
approximately 45 sites, at serine and threonine residues (Drewes, Trinczek et al. 1995, 
Geschwind 2003, Hanger, Anderton et al. 2009). The microtubule binding domains 
(MBDs) of tau confer a positive charge to the protein, allowing it to stably bind the 
negatively charged microtubules (Duff, Knight et al. 2000). In the disease state tau 
becomes hyperphosphorylated, resulting in the neutralization of its net positive charge 
(Fig. 1.3). This causes tau to dissociate from the microtubules and aggregate to form 
paired helical filaments (PHFs) with other hyperphosphorylated tau molecules (Alonso, 
Zaidi et al. 2001, Geschwind 2003, Hernandez and Avila 2007). Upon the dissociation of 
tau, the microtubule network becomes destabilized and axonal transport may be disrupted 
(Cuchillo-Ibanez, Seereeram et al. 2008). Over time, PHFs will accumulate to form 
neurofibrillary tangles, primarily in pyramidal neurons (Iqbal, Alonso Adel et al. 2005). 
1.1.4 Frontotemporal dementia (FTD) and other Tauopathies 
Tau pathology is not isolated to AD. There are several neurodegenerative diseases 
which also have pathology associated with the tau protein, these diseases are classified as 
‘tauopathies’(Lee, Goedert et al. 2001). Tauopathies are associated with a variety of 
neurodegenerative diseases involving dementia and/or motor dysfunctions. AD is the 
most well-known tauopathy, and involves gradual neurodegeneration radiating from the 
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entorhinal cortex, primarily causing cognitive decline in early stages of the disease 
(Yassa 2014). Other tauopathies, such as progressive supranuclear palsy (PSP), develop 
distinctly different high order tau structures (straight filaments instead of paired helical 
filaments in AD) in different areas of the brain than seen in AD, resulting in different 
clinical features. Often misdiagnosed as Parkinson’s disease, PSP patients suffer from 
bradykinesia, dysphagia, ophthalmoplegia, and eventually dementia (Steele, Richardson 
et al. 1964, Oba, Yagishita et al. 2005, Louis, Babij et al. 2013). In this disease tangles 
form in neurons and glial cells of the substantia nigra, subthalamic nucleus, oculomotor 
nucleus, and a variety of other structures in the mesencephalon (Barsottini, Felicio et al. 
2010). PSP is just one of many other tauopathies, all of which are phenotypically varied 
but mechanistically unified by the aggregation of the tau protein. 
For many years it was unclear as to what initiated the development of tau 
pathology in AD, and whether tau pathology alone could cause dementia. Because of this 
tau pathology was largely disregarded as a byproduct of neurodegeneration or other 
pathological changes. It wasn’t until the late 1990s that studies began to indicate tau may 
play a larger role than previously suggested, as familial tau mutations were discovered to 
promote the development of pathology and induce neurodegeneration and dementia in 
patients with frontotemporal dementia and parkinsonism linked to chromosome-17 
(FTDP-17)(Hutton, Lendon et al. 1998, Poorkaj, Bird et al. 1998, Spillantini, Murrell et 
al. 1998, Morris, Khan et al. 2001). These tau mutations are observed in approximately 
30% of FTD diagnoses, but there are no mutations in tau associated with AD (Morris, 
Khan et al. 2001, Rosso, Donker Kaat et al. 2003). With the discovery of these mutations, 
37 to date, many new mechanisms by which tau pathology can develop have been 
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discovered (Goedert and Jakes 2005). Mutations within intronic regions have been shown 
to modulate splicing of tau mRNA, resulting in unequal N-terminal repeat isoforms (4R 
to 3R) expression, which promotes the development of pathology (D'Souza, Poorkaj et al. 
1999, Grover, Houlden et al. 1999, Yoshida, Crowther et al. 2002). Mutations found 
within the exons, such as P301L and P301S in exon 10, promote the formation of tau 
filaments, and pathogenesis (Hong, Zhukareva et al. 1998, Mirra, Murrell et al. 1999, 
Rizzu, Joosse et al. 2000). These mechanisms which allow tau pathology to develop 
independent of other known initiating factors have been useful insights into better 
understanding a plethora of related neurodegenerative diseases.  
1.2 – Obesity and Diabetes 
1.2.1 – Background and Prevalence 
Obesity is a disorder in which an individual has excessive adipose stores, and is 
defined in adults by a body mass index, a measure of weight divided by the square of a 
person’s height, of over 30kg/m2 (Mokdad, Serdula et al. 1999, Haslam and James 2005). 
The World Health Organization officially declared obesity an epidemic in 1997, and has 
since called childhood obesity the “most serious global public health challenge for the 
21
st
 century” (Caballero 2007). Obesity is the leading preventable cause of death 
worldwide, and is associated with many life-threatening diseases such as type 2 diabetes 
mellitus (T2DM), cardiovascular disease, and chronic obstructive pulmonary disease 
(Haslam and James 2005, Poulain, Doucet et al. 2006). Currently there are no viable 
pharmaceutical therapies which reduce body weight and the most successful intervention 
to date is bariatric surgery (Colquitt, Picot et al. 2009, Chang, Stoll et al. 2014). 
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T2DM is highly correlated with obesity and has been a gradually growing issue 
across the world for the last 50 years. Obesity is a common driving factor for the 
development of T2DM and the two diseases are highly associated, with 85.2% of T2DM 
patients being classified as overweight or obese (Ford, Williamson et al. 1997, Resnick, 
Valsania et al. 2000, Mokdad, Ford et al. 2003, Prevention 2011). T2DM greatly 
increases the risk of developing other pathologies, including cardiovascular disease, renal 
dysfunction, and dementias (Rewers, Zaccaro et al. 2004, Xu, Qiu et al. 2009, Seshasai, 
Kaptoge et al. 2011, Association 2013). T2DM accounts for approximately 90% of all 
diabetes diagnoses, affecting over 25 million individuals in the U.S. (Adeghate, Schattner 
et al. 2006, Prevention 2011).  
 Obesity is not the only factor which can promote the development of T2DM. High 
sugar consumption, lack of exercise, increased intake of partially hydrogenated fats, and 
even residing in urban areas all increase the risk of developing T2DM (Riserus, Willett et 
al. 2009, Abdullah, Peeters et al. 2010, Malik, Popkin et al. 2010, Lee, Shiroma et al. 
2012). Hereditary factors can also influence the development of the disease. Mutations in 
PPARγ, AKT2, TCF7L2, and the insulin receptor gene are associated with increased risk 
of T2DM (Malecki 2005, Sladek, Rocheleau et al. 2007). Additionally, other medical 
conditions can promote the development of T2DM, for example, women who develop 
gestational diabetes are at a greater risk after pregnancy (Dornhorst and Rossi 1998, 
Bellamy, Casas et al. 2009).  
1.2.2 – Associated pathologies 
T2DM is a metabolic disorder associated with insulin resistance, pancreatic β-cell 
degeneration, and inappropriate signaling events (Insulin resistance, elevated glucagon 
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release, failure of glucose transporter recruitment, and reduced lipolysis to name a few), 
which ultimately result in whole body glucose mishandling (Baker, Cross et al. 2011, 
Accardi, Caruso et al. 2012, Bergman 2013).  Insulin resistance primarily develops in 
hepatocytes and skeletal muscle cells. Insulin resistance in hepatocytes or muscle cells 
prevents the cells’ ability to uptake free glucose. Additionally, elevated glucagon release 
from alpha-islets promotes mobilization of glycogen stores in the liver and 
gluconeogenesis (D'Alessio 2011). This dysfunctional glucose handling results in highly 
variable and uncontrolled blood glucose levels, and leaves the body prone to disease.  
 As blood glucose levels remain high for long periods of time endothelial cells 
lining the walls of the vasculature take up excessive quantities of these sugars. As result 
more glycoproteins are generated on the surface of these cells promoting the generation 
of advanced glycation end-products (AGEs) which damage the underlying basement 
membrane, making it weaker (Rahman, Rahman et al. 2007, Cade 2008). These vascular 
changes can be classified as microvascular, in dealing with smaller structures such as 
capillaries, or macrovascular which affect larger vessels (Clark and Lee 1995, Cooper, 
Bonnet et al. 2001).  
 Microvascular pathology can result in the failure of major organ systems. For 
example, diabetic retinopathy (the most common cause of blindness in the non-elderly) is 
characterized by hemorrhages in the retina or edema of the macula (Orchard, Dorman et 
al. 1990, Sheetz and King 2002). Similarly, in diabetic nephropathy the kidneys can 
develop thickening of glomerular basement membranes, undergo hyperfiltration, develop 
albuminuria, and end-stage renal disease before progressing to complete kidney failure 
(Brenner, Cooper et al. 2001, Chen, Hong et al. 2001, Drummond, Mauer et al. 2002). 
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Peripheral neuropathy can also be associated with microvascular abnormalities, which 
may result in thickening of the basement membrane, demyelination of neurons, 
endoneurial hypoxia (Young, Veves et al. 1992, Ibrahim, Harris et al. 1999). 
Macrovascular changes can be just as deleterious, as changes to the seen in 
microvascular pathologies. Cardiovascular disease is the leading cause of death in those 
with T2DM. T2DM patients have the same risk of myocardial infarct as non-diabetic 
individuals who have suffered previous infarcts (Laakso 1999, Nazimek-Siewniak, 
Moczulski et al. 2002). This effect can be a result of high LDL cholesterol, low HDL 
cholesterol, hypertension, and high triglyceride levels observed in T2DM which can lead 
to atherosclerosis (Lehto, Ronnemaa et al. 1997, Facchini, Hua et al. 2001, Beckman, 
Creager et al. 2002, Reusch and Draznin 2007). Cardiovascular disease isn’t the only 
result of macrovascular insult associated with T2DM. The development of 
cerebrovascular disease is 200-300% higher in patients with T2DM than those without, 
and commonly results in ischemic strokes (Muntean, Mitrea et al. 2012). 
1.2.3 – Influences of Obesity and T2DM on Neurodegeneration 
T2DM contributes to approximately 20% of all cases of cerebrovascular disease 
(Stegmayr and Asplund 1995, Tuomilehto, Rastenyte et al. 1996). T2DM patients with 
cerebrovascular disease are more likely to die from an ischemic event, and those who do 
survive are more likely to suffer from a disability (Haheim, Holme et al. 1995, 
Elneihoum, Goransson et al. 1998, Megherbi, Milan et al. 2003, Ribo, Molina et al. 
2005). Aside from the neurons and glial cells killed directly by an ischemic event, the 
subsequent fallout (hypoxia induced cell death, inflammation, excitotoxicity, 
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accumulation of reactive oxygen species, etc.) makes surviving cells more susceptible to 
death, leaving the individual more likely to develop dementia (Mattson, Duan et al. 2001, 
Roman 2003). Large epidemiological cohort studies put the chance of individuals 
developing dementia after stroke at five to nine times greater than the general population 
(Tatemichi, Desmond et al. 1992, Tatemichi, Paik et al. 1994, Kokmen, Whisnant et al. 
1996). Additionally, high hip-to-waist ratio and poor diet, characteristics associated with 
T2DM, independently increase risk of stroke (O'Donnell, Xavier et al. 2010). 
The Rotterdam Study explored the effects of T2DM in a large cohort of 
individuals and revealed 8.8% of dementia cases were likely a result of T2DM (Ott, Stolk 
et al. 1999). The authors in this study proposed that AGE generation in T2DM may play 
an important role in disease development as AGE receptors are increased in the AD brain 
(Yan, Chen et al. 1996, Munch, Schinzel et al. 1998, Ott, Stolk et al. 1999).  Since the 
Rotterdam Study other studies have implicated other mechanisms which may contribute 
to neurodegeneration in T2DM. Insulin has been shown to protect primary rat neurons 
from apoptosis, a process which is less likely to occur in the insulin resistant brain 
(Tanaka, Sawada et al. 1995). Additionally, intact insulin receptor signaling is associated 
with increased water-maze performance in rats (Zhao, Chen et al. 1999). High fat diet 
and excessive weight gain promote the generation of ceramides in hepatocytes. These 
lipid species are highly neurotoxic and easily cross the blood brain barrier (Lyn-Cook, 
Lawton et al. 2009).  Though the effects of insulin have been thoroughly explored in 
relation to neurodegeneration, there are other major hormones which undergo huge 
changes in disease. 
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1.3 – Leptin 
1.3.1 – Background and Signaling 
Leptin is an adipokine released from white adipose tissue, and serum levels 
correlate to body fat content. Leptin and its effects were discovered by the Jackson 
Laboratories when a mouse line with mutations in the ob gene was found to be obese due 
to an insatiable appetite (Ingalls, Dickie et al. 1950). Following this discovery, another 
obese mouse line with a mutation in the db gene was discovered (Hummel, Dickie et al. 
1966). Further analysis of the ob and db genes revealed the ob gene codes for leptin itself 
and the db gene codes for the leptin receptor (Coleman 1978). Both of these lines are 
hyperphagic, hyperglycemic, and display elevated plasma insulin and develop frank 
diabetes as early as weaning (Coleman 1978). 
The leptin receptor is highly expressed in the hypothalamus, and signaling 
through the receptor modulates energy expenditure and satiety (Ahima, Prabakaran et al. 
1996). Leptin secretion occurs according to circadian cues, being released mostly at night 
to suppress hunger signals while sleeping (Sinha, Ohannesian et al. 1996, Licinio, 
Mantzoros et al. 1997). Upon activation of the leptin receptor Janus Kinase and Signal 
Transducer and Activator of Transcription (JAK/STAT) and PI3K signaling cascades are 
activated (Figure 1.4) (Bates, Stearns et al. 2003). Upon activation STAT translocates to 
the nucleus where it regulates expression of satiety signals and energy expenditure 
(Myers, Cowley et al. 2008).  
Interestingly, multiple isoforms of the leptin receptor are found throughout the 
brain, and yet little is known about leptin’s role outside of canonical hypothalamic energy 
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regulation (Tartaglia, Dembski et al. 1995, Chen, Charlat et al. 1996, Cioffi, Shafer et al. 
1996, Lee, Proenca et al. 1996).  
1.3.2 – Neuroprotective Effects and Leptin Resistance 
 Recent evidence suggests leptin may play a role outside of basic metabolic 
reglation. In 2009 Lieb et. al. found plasma leptin levels positively correlated with 
memory and cognition and negatively correlated to incidence of dementia (Lieb, Beiser et 
al. 2009). In a study by the AD Neuroimaging Initiative (ADNI), approximately 70% of 
individuals with mild cognitive impairment (MCI) display significantly decreased plasma 
leptin levels, half of these individuals also carry the Apolipoprotein-E4 (APOE-ε4) allele 
(Johnston, Hu et al. 2014). Administration of leptin to transgenic mouse models of AD 
reduces the development of both amyloid and tau pathology while also improving 
cognitive performance (Fewlass, Noboa et al. 2004, Greco, Bryan et al. 2009, Greco, 
Bryan et al. 2010). A better understanding of the underlying mechanisms which impart 
these neuroprotective effects is highly sought after.  
 The leptin receptor is expressed throughout the brain and is highly expressed in 
the hippocampus, piriform cortex, cerebellum, and especially high in the reward centers 
of the ventral tegmental area and substantia nigra (Elmquist, Bjorbaek et al. 1998, 
Figlewicz, Evans et al. 2003).  Leptin promotes NMDA mediated synaptic plasticity 
within the rat hippocampus, a mechanism which is thought to be activated via PI3K, 
MAPK, and Src kinase signaling cascades (Shanley, Irving et al. 2001). Additionally, 
leptin has been shown to protect dopaminergic neurons from a mouse model of 
dopaminergic cell death via MAPK signaling (Weng, Signore et al. 2007). The same 
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study showed leptin’s effects to be blocked when JAK2 and GRB2 (downstream 
signaling transducers) were knocked down, preventing MAPK activation. Leptin 
treatment at physiological concentrations increases serine-9 phosphorylation of GSK-3β, 
a potent tau kinase, which inhibits GSK-3β enzymatic activity (Valerio, Ghisi et al. 
2006). Interestingly, insulin also promotes the inactivation of GSK-3β, and therefore 
reduce tau phosphorylation, but only at concentrations 100 greater than is required of 
leptin to see the same effects (Lesort, Jope et al. 1999, Planel, Tatebayashi et al. 2007, 
Greco, Sarkar et al. 2008).  
Chronic obesity results in gradual desensitization of the leptin receptor to its 
ligand. The mechanism by which this occurs is unknown, but it is the primary reason 
leptin itself cannot be used as a therapeutic. One proposed hypothesis suggests negative 
feedback cascades, which function via suppressor of cytokine signaling-3 (SOCS-3), 
which inhibits the tyrosine phosphorylation of the receptor, preventing its activation 
(Bjorbaek, El-Haschimi et al. 1999, Myers, Cowley et al. 2008). Another proposed 
mechanism suggests the ability of leptin to cross the blood brain barrier is impaired, 
preventing leptin from accessing hypothalamic leptin receptors (Uotani, Bjorbaek et al. 
1999, Myers, Cowley et al. 2008). It is important to better understand the mechanisms 
involved in leptin resistance, as reduced leptin signaling will negate the neuroprotective 
effects of leptin.  
1.4 – Rationale of Study 
 Obesity and T2DM impart increased risk for developing neurodegenerative 
disease directly via dysfunctional signaling events, or indirectly through other pathologic 
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events associated with the disease states. With the global rise in obesity and T2DM rates 
investigation into the underlying etiology of these mechanisms is warranted. It is not 
clear as to how obesity and T2DM promote pathogenesis or exactly what types of 
pathology are impacted. 
 Recently, out lab showed that total Aβ in the brain levels negatively correlate with 
plasma leptin levels. These results are supportive of other observations in the literature 
(Morrison 2009). Interestingly, it is known that leptin resistance occurs in chronically 
obese individuals, and it is probable that the neuroprotective effects of leptin are lost. 
Therefore, the purpose of this study was to determine if leptin resistance, and the 
associated obesity and diabetes, may impart an increased chance for developing 
neurodegenerative disease. The results of this study will advance the field of 
neurodegeneration and have important implications for obesity, T2DM, AD, and 
tauopathies.   
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Figure 1.1 APP Processing and Generation of Toxic Beta-Amyloid. 
APP is a transmembrane protein which can be processed by either the non-amyloidogenic 
or amyloidogenic pathways. Upper panel: During non-amyloidogenic processing, an 
enzymatic activity called α-secretase cleaves APP (1) to generate a soluble N-terminal 
fragment (sAPPα) and an 83 amino acid C-terminal fragment (C83). Next, the γ-secretase 
complex (2), with PS1 acting as the catalytic subunit, cleaves the C83 fragment within 
the transmembrane domain, releasing a secreted peptide known as P3. Lower panel: In 
amyloidogenic processing, an enzymatic activity called β-secretase (1) cleaves APP to 
generate different soluble N-terminal (sAPPβ) and C-terminal (C99) fragments. Cleavage 
of the C99 fragment by γ-secretase (2) results in the generation of the Aβ peptide. 
Processing of APP in either pathway results in the production of an APP intracellular 
domain (AICD) with poorly defined function. 
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Figure 1.2 A Simplified Overview of the Amyloid Cascade Hypothesis. 
One version of the amyloid cascade hypothesis proposes that the increase in Aβ 
biosynthesis, resulting from alterations in APP processing, drives AD pathogenesis. 
Aggregation of Aβ results in the formation of neuritic plaques, increased oxidative stress, 
and NFT formation, resulting in neurodegeneration. Other variations are possible. For 
example, altered clearance of Aβ likely plays a significant role in disease progression.  
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Figure 1.3 Tau Hyperphosphorylation Leads to Neurodegeneration. 
Tau is a cytosolic microtubule stabilizing protein. Under normal conditions tau’s 
phosphorylation state is dynamic, undergoing constant cycling of phosphorylation and 
dephosphorylation to stabilize microtubules. If tau becomes hyperphosphorylated it will 
dissociate from microtubules, bind to other hyperphosphorylated species, and form higher 
order structures, such as oligomers, filaments, and NFTs. 
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Figure 1.4 Leptin Signaling. 
Leptin binds to its receptor, initiating a phosphorylation cascade, activating the Janus 
Kinase (JAK). JAK can initiate a cascade of signaling events via the PI3K/AKT and 
MAPK pathways and alter gene expression by phosphorylating the Signal Transducer 
and Activator of Transcription (STAT). Upon STAT phosphorylation it homodimerizes 
and translocates to the nucleus where it alters gene expression, promoting increased 
energy expenditure and satiety.  
 
 
 
 
 
 
 
 
 
 
 
Copyright © Thomas L. Platt 2014  
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CHAPTER 2: General Materials and Methods 
2.1 – Cell Lines and Lysis Protocol 
 Human SH-SY5Y neuroblastoma cells were purchased from ATCC, and were 
cultured in Dulbecco’s Modified Eagle Media (DMEM; Hyclone; Thermo Scientific, 
Waltham, MA). Human H4 neuroglioma cells stably overexpressing APP
(KM670/671NL)
 
mutant were grown in Opti-MEM (Invitrogen; Life Technologies, Carlsbad, CA) with 
200 µg/mL hygromycin as a selective agent. HEK293 human embryonic kidney cells 
with Tau
(P301L)
 mutant, a gift from Dr. Chad Dickey, were grown in DMEM with 200 
µg/mL G418 selective agent. All culture media was supplemented with 10% fetal bovine 
serum (FBS; HyClone) and 1% 5,000 µg/mL Penicillin-Streptomycin (Penn-Strep; Lonza 
Group, Basel, Switzerland). All cell lines were grown in a humidified incubator at 37ºC 
with 5% CO2. Cells were cultured and maintained in cell culture hood. Other specific 
details regarding culturing techniques will be discussed for each set of experiments. 
 To preserve cell lines plugs of cells were cryoprotected and frozen at a density of 
approximately of 10
6
 cells per vial. Cells were grown to ~70% confluence in T-75 flasks 
(#BD353136; Falcon; Corning Inc., Corning, NY;), media was removed, cells rinsed in 5 
mL phosphate-buffered saline (PBS), then incubated in 0.25% w/v trypsin (Gibco; Life 
Technologies) in the incubator at 37ºC for approximately 5 minutes. Once completely 
dissociated with the flask cells were transferred to a 15 mL conical tube and centrifuged 
at 500 x g for 5 minutes. Trypsin was aspirated from the pellet, the cells were 
resuspended in 1x PBS to rinse any remaining trypsin from the cells, and then spun again 
at 500 x g for 5 minutes. The PBS was aspirated and the pellet was resuspended in 6 mLs 
of a 90% FBS (HyClone) 10% DMSO cryopreservation solution. 1 mL of the resulting 
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suspension was aliquoted into six cryopreservation vials to have each aliquot containing 
one mL of a 1,000,000 cells/mL suspension. Vials were frozen in an isopropanol chamber 
at -80ºC overnight, and then transferred to liquid nitrogen the following day.  
 Rat hippocampal neurons were provided to us by Irena Artiushin from Dr. Chris 
Norris’ lab. Neurons were collected from E18 Sprague Dawley rat pups and plated on 
poly-L-lysine coated 35 mm dishes in Minimum Essential Media (MEM) with 10% FBS 
and 10% horse serum, and supplemented with 15 µg/mL 5-fluoro-2-deoxyuridine to 
inhibit growth of non-neuronal cells. As with other cultures these cells were incubated in 
a 37ºC incubator with 5% CO2. Cells were cultured for four weeks before they were used 
in studies. 
Prior to lysis, media was aspirated from wells and cells were rinsed in 1x PBS.  
Cells were then incubated in chilled radio-immunoprecipitation assay (RIPA) buffer (150 
mM NaCl/0.1% SDS/0.5% sodium deoxycholate/50 mM Tris-Base/1% Triton X-100; pH 
8.0) with 1 x protease inhibitor cocktail (PIC; Amresco, Solon, OH), and (when 
measuring phosphorylated proteins) 1 x phosphatase inhibitor cocktail (PhIC; EMD 
Millipore, Billerica, MA). Plates were chilled on ice for ~10 minutes. Following lysis, 
cell scapers (X) were used to remove any remaining adherent cells from each well. Cell 
lysate was triturated and pipetted into 1.5 mL Eppendorf tubes and centrifuged at 20,000 
x g at 4ºC for 5 minutes. The supernatant was removed for assay and the pellet discarded. 
2.2 – Animal Husbandry, Metabolic Measures, and Behavioral Analysis 
 All husbandry and treatment procedures were conducted with prior approval of 
the University of Kentucky’s Institutional Animal Care and Use Committee (IACUC; 
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protocol # 2010-0673), in accordance with PHS guidelines. Leptin receptor deficient 
mice were purchased from the Jackson Laboratory (B6.BKS(D)-Lepr
db
/J, stock # 000697, 
hereafter referred to as db mice) and were housed two or three mice per cage with ab 
libitum access to food and water on a 12 hour light/dark cycle. These founders were bred 
to establish a colony. Approximately 10 days after birth tails snips were collected and 
were used for genotyping by SNP-specific Taqman®-based qPCR using a Taqman® 
genotyping kit (Applied Biosystems by Life Technologies; Grand Island, NY). All db 
homozygous mice were monitored weekly, measuring each animal’s weight, coat 
appearance, gait, and body condition score to identify any potential health issues. If any 
adverse issue arose, the Division of Laboratory Animal Resources (DLAR) veterinary 
technicians were contacted to inspect the mice and advise on treatment.  
 At different timepoints in each study group mice underwent metabolic testing by 
performing glucose tolerance tests (GTTs) and/or insulin tolerance tests (ITTs). Six hours 
before testing mice were removed from their home cages and placed into new cages 
without access to food in a quiet procedure room. After a six hour fast, mice were 
injected intraperitoneally with a bolus of either glucose (2g/kg body weight) or insulin 
(0.75 U/kg body weight), depending on the metabolic test being performed. At 0, 15, 30, 
60, and 120 minutes blood glucose was measured by taking a small drop of blood via tail 
nick of each mouse. In case of adverse event, QuickStop coagulant was on hand to use in 
case of excessive bleeding and a bolus of glucose (2g/kg bodyweight) was ready to 
rescue any mice from the ITT. In the course of these experiments no adverse events 
occurred which required rescuing. At the end of the test mice were placed into a new 
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cage with a hopper of fresh food. The following day each animal was checked for any 
complications related to the experiment.  
 Cognitive impairment was measured by performing a modified Morris Water 
Maze (MWM) test. At the beginning of each test day mice were individually placed into 
clean cages on heating pads to acclimate. After 20 minutes of acclimation mice were 
introduced into a 134.5 cm diameter pool, and were given 60 seconds to find a 
submerged 11 cm diameter circular platform. Visual cues were placed around the 
platform to provide spatial reference to allow the mice to remember where the platform 
was. If mice did not find the platform within the 60 seconds, they were placed on the 
platform for 15 seconds to acquaint them with the platform location. Mice were given 
five minutes of rest between trials. Mice were trained over a five day period using a 
submerged platform running four 60-second trials each day. At the end of training on the 
fifth day the platform was removed and a 60 second probe trial was performed. In the 
probe trial the platform is removed and the time mice spend in the target quadrant 
(quadrant where the platform was during the trials) and target zone (zone where the 
platform was during the trials) as a measure of memory and learning. Additionally, after 
the probe trial, a visual acuity trial was performed. In the visual acuity trial the platform 
was moved to the opposite side of the pool and a small white marker placed on top of the 
platform. All trials were captured using a video camera and analyzed with EthoVision XT 
software (Noldus Information Technology, Leesburg, VA) to measure swim distance, 
escape latency and swim velocity. 
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2.3 – Tissue Collection and Processing 
 When mice were to be sacrificed a lethal dose of Beuthanasia-D (Schein-Plough 
Animal Health, Union, NJ) was administered intraperitoneally and after signs of life were 
no longer apparent animals were decapitated as a secondary means of euthanasia. The left 
hemibrain was collected and drop-fixed in 10% saline-buffered formalin for 
approximately a week, and then transferred to 1x PBS containing 0.05% sodium azide for 
storage. The right hemibrain was immediately frozen on dry ice for future extraction. 
Whole blood, attained from trunk bleeding after decapitation, was collected into EDTA 
containing tubes and centrifuged at 1,500 x g for 10 minutes. After centrifugation the 
plasma supernatant was pipetted off into 1.5 mL tubes and frozen on dry ice for future 
analysis.  
 Frozen brain tissue (from mice or humans) was homogenized with an AHS200 
PowerMax polytron (VWR, Radnor, PA) in 1x RIPA with PIC (Amresco) and PhIC 
(EMD Millipore) at 1mL per 200µg tissue. Insoluble material was separated by 
centrifugation at 13,000 x g for 15 minutes at 4°C. Supernatants were transferred to 1.5 
mL tubes and frozen at -80ºC, and the pellet discarded. The protein concentrations of the 
supernatants were calculated by bicinchoninic acid (BCA) assay (Pierce, Rockford, 
Illinois). 
2.4 – Statistical Analysis 
 All data were analyzed using SPSS software version 22 (IBM; Armonk, New 
York) or Prism version 5 (GraphPad Software, La Jolla, CA). Group comparison data 
were analyzed by general linear model ANOVA and post-hoc comparisons made using 
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Tukey-HSD or Dunnett’s tests. When analyzing human data, age, gender, and PMI were 
used as co-varying factors. Correlations were analyzed as Pearson’s product test for 
parametric analysis or Spearman’s rank order test for non-parametric analysis. Repeated 
measures were analyzed using linear mixed models with time as categorical predictors. 
Specific statistical information and procedures are outlined in figure legends.  
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Thomas L. Platt 2014 
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CHAPTER 3: Tau and Neurodegenerative Disease 
Portions of this chapter are reprinted with permission from: 
Holler CJ, Davis PR, Beckett TL, Platt TL, Webb RL, Head E, Murphy MP. Bridging 
Integrator 1 (BIN1) Protein Expression Increases in the Alzheimer’s Disease Brain and 
Correlates with Neurofibrillary Tangle Pathology (Accepted) 
Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, Platt TL, Murphy MP, Morley JE, 
Kumar V, Butterfield DA (2014).Antisense oligonucleotide against GSK-3β in brain of 
SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement 
of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med. 
(2014) 67:387-95 
3.1 – INTRODUCTION 
 
Tau plays an interesting role in neurodegeneration. Tau is associated with many 
forms of neurodegenerative disease and is likely the sole cause of degeneration in some 
of those diseases. However, aside from genetic mutation, tau rarely initiates the disease 
process and typically results from other insult. For example, dementia pugilistica is a 
tauopathy which results from repeated brain injury and was first described in boxers 
(Mendez 1995, Erlanger, Kutner et al. 1999). The amyloid cascade hypothesis of AD 
posits that Aβ is the central insult which initiates the development of tau pathology 
(Selkoe 1991, Hardy and Higgins 1992).  
 Though no cure for tauopathies exists, several groups suggest tauopathies can be 
attenuated by inhibiting GSK3β activity.  GSK3β is a proline-directed serine/threonine 
protein kinase that is involved in a variety of pathways modulating cellular metabolism 
and gene expression (Welsh and Proud 1993, Grimes and Jope 2001, Turenne and Price 
2001). GSK3β was first discovered to inactivate glycogen synthase, and has since been 
shown to play a key role in glycogen metabolism (Embi, Rylatt et al. 1980, Woodgett 
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1990). GSK3β is highly expressed in the brain and is mainly found in neurons and 
astrocytes (Woodgett 1990, Yao, Shaw et al. 2002, Perez-Costas, Gandy et al. 2010). 
Knocking out GSK3β is embryonic lethal as shown in mice (Hoeflich, Luo et al. 2000). 
This lethality is likely a result of GSK3β’s important role in development. GSK3β 
signaling regulates transcriptional expression of key developmental proteins, regulates 
apoptotic signals, and axonal formation (Hoeflich, Luo et al. 2000, Kim, Zhou et al. 
2006, Garrido, Simon et al. 2007, Liang and Chuang 2007, Kim, Wang et al. 2009, 
Mines, Beurel et al. 2011).   GSK3β is constitutively active and is negatively regulated by 
Wnt, insulin, and leptin signaling pathways which phosphorylate GSK3β at the serine-9 
residue (Stambolic and Woodgett 1994, Saltiel and Kahn 2001). Serine-9 
phosphorylation blocks entry of primed phosphorylation substrates, preventing GSK3β 
kinase activity (Harwood 2001). Phosphorylation of tyrosin-216 promotes GSK3β 
activity (Hughes, Nikolakaki et al. 1993, Bijur and Jope 2001, Buescher and Phiel 2010).  
Increased GSK3β activity and expression has been implicated in 
neurodegenerative processes (Schaffer, Bertram et al. 2008).  Inhibition of PI3K and 
Wnt, key inhibitors of GSK3β, impairs learning and memory, and overexpression of 
GSK3β inhibits the induction of long-term potentiation (LTP) and promotes long-term 
depression (LTD) (Sanna, Cammalleri et al. 2002, Chen, Park et al. 2006, Hooper, 
Markevich et al. 2007, Peineau, Taghibiglou et al. 2007).  
Recent evidence suggests GSK3β plays a vital role in AD pathogenesis. Aside 
from increased tau hyperphosphorylation, elevated GSK3β activity and the generation of 
Aβ are tightly associated, though it is not clear if increased GSK3β activation results in 
increased Aβ production or vice versa (Hernandez, Gomez de Barreda et al. 2010, 
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DaRocha-Souto, Coma et al. 2012, Avrahami, Farfara et al. 2013, Reddy 2013). GSK3β 
localizes with dystrophic neurites and NFTs, and displays increased activity within pre-
tangle containing neurons and frontal cortex of AD brains, and expression of GSK3β is 
elevated within the hippocampus of AD patients (Shiurba, Ishiguro et al. 1996, Pei, Braak 
et al. 1999, Blalock, Geddes et al. 2004). Additionally, a polymorphism in GSK3β has 
been implicated as a promoter of late onset AD (Mateo, Infante et al. 2006). 
Enzymatic dysregulation of tau kinases are not the only ways in which tau 
pathology can be initiated. Alternative splicing of the tau gene yields 6 tau isoforms, half 
with 3 microtubule binding domains (3R) and the other half with 4 microtubule binding 
domains (4R) (Goedert, Spillantini et al. 1989, Goedert, Spillantini et al. 1989). Normal 
adult tissues contain an equal distribution of 3R and 4R isoforms and unequal 3R to 4R 
ratios have been observed in tauopathies (Goedert, Spillantini et al. 1989, Andreadis, 
Broderick et al. 1995). Unequal splicing of tau exon 10 results in an imbalance of 3R and 
4R containing isoforms (Goedert, Spillantini et al. 1989, Goedert and Jakes 1990, 
Andreadis, Brown et al. 1992). 4R:3R ratios are found to be elevated in several 
tauopathies such as corticobasal degeneration, AD, PSP, and FTD (Flament, Delacourte 
et al. 1991, Sergeant, Wattez et al. 1999, Tolnay, Sergeant et al. 2002).  
The mechanism by which disruption of the equimolar ratio of 3R to 4R isoforms 
promotes pathology is unknown. 4R isoforms more readily bind microtubules and it is 
possible this increased binding affinity could promote tau’s ability to aggregate (Goedert 
and Jakes 1990, Panda, Samuel et al. 2003). It is interesting to note that many animals 
which don’t develop tauopathies, such as mice, express only 4R isoforms in the adult 
brain (Lee, Cowan et al. 1988). However, when mice express all six human tau isoforms, 
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both 3R and 4R, with no mutations to promote pathogenesis, tau hyperphosphorylation 
and aggregation occurs (Andorfer, Kress et al. 2003). These findings suggest the presence 
and interactions of both tau isoforms promote pathogenesis. In fact, a recent study 
revealed equimolar concentrations of 3R and 4R tau isoforms reduces tau fibrilization, 
whereas ratios with higher levels of 4R isoforms promoted tau fibrilization (Adams, 
DeTure et al. 2010).   
 Myotonic dystrophy (DM) is a disease in which tau pathology develops due to 
dysfunctional splicing events (Kiuchi, Otsuka et al. 1991, Vermersch, Sergeant et al. 
1996). Type 1 DM consists of a trinucleotide repeat CUG in the 3’ untranslated region of 
myotonic dystrophy protein kinase (DMPK) (Ashley and Warren 1995). Type 2 DM 
consists of a similar tetranucleotide CCTG repeat in the cellular nucleic acid binding 
protein (CNBP) within intron 1 of ZNF9 (Liquori, Ricker et al. 2001). Traditionally these 
diseases are associated with muscle wasting but have many other associated symptoms as 
a result of splicing abnormalities (Ashley and Warren 1995, Korade-Mirnics, Babitzke et 
al. 1998, Day, Roelofs et al. 1999, Udd, Meola et al. 2011). The mRNA repeats in DM 
act as gain of function mutations, resulting in sequestration of splicing machinery to 
repeat regions, leaving other transcripts which require splicing unprocessed (Mankodi, 
Logigian et al. 2000). In type 1 DM a reduction in tau exon 2 and an increase in exon 10 
inclusion, and a reduction in exon 2 and 3 inclusion in type 2 DM (Sergeant, Sablonniere 
et al. 2001, Maurage, Udd et al. 2005, Dhaenens, Tran et al. 2011). It is likely disruption 
of normal tau isoform ratios result in tau pathogenesis.  
 In tauopathies, several forms of tau aggregates exist: oligomers, PHFs, NFTs, and 
many intermediates. The number of NFTs and severity of phenotype are closely 
34 
 
correlated, therefore, it has traditionally been believed that NFTs induce 
neurodegeneration in tauopathies (Bierer, Hof et al. 1995, Santacruz, Lewis et al. 2005). 
Contrary to this belief, transgenic animal models overexpressing non-mutant human tau 
do not develop NFTs yet neurodegeneration still occurs (German, Quintero et al. 2001, 
Wittmann, Wszolek et al. 2001, Andorfer, Acker et al. 2005). Additionally, NFTs are 
detected in healthy individuals and it has been posited that NFTs can persist for up to 30 
years in neurons without inducing neurodegeneration. These data  suggests NFTs may 
play another role within the brain (Morsch, Simon et al. 1999).  
It has been proposed that NFTs actually play a neuroprotective role and may not 
be toxic to cells (Lee, Perry et al. 2005, Congdon and Duff 2008). Lee et al. propose that 
NFT formation is a compensatory mechanism against reactive oxygen species, where in 
response to oxidative stress tau kinases become activated and promote 
hyperphosphorylation of tau and NFT formation (Lee, Perry et al. 2005). Additionally, 
some have suggested other tau species are cytotoxic whereas NFTs are benign. Tian et al. 
demonstrated that 4R trimeric tau is toxic to SH-SY5Y cells while monomers and dimers 
are not (Tian, Davidowitz et al. 2013). Hippocampal injections of tau monomers, 
oligomers, and tau fibrils into C57BL/6 mice demonstrated that oligomer injection 
impaired recognition memory, induced synaptic loss, and resulted in neurodegeneration 
(Lasagna-Reeves, Castillo-Carranza et al. 2011).  
In this chapter we explore some of the aforementioned mechanisms to provide a 
better understanding of tau pathogenesis. Utilizing antisense oligonucleotides we 
inhibited expression of GSK3β and demonstrated that this reduction lowered levels of tau 
phosphorylation. We demonstrated that protein expression is altered in the human DM 
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brain, which indicates splicing abnormalities may promote pathogenesis. Finally, we 
show that recombinant tau oligomers are toxic to both primary rat hippocampal neurons 
and SH-SY5Y cells, further supporting the role of tau oligomers in neurodegeneration.  
3.2 – METHODS 
3.1 – Subjects 
Human tissue samples were acquired from the NICHD Brain and Tissue Bank for 
Developmental Disorders at the University of Maryland, three myotonic dystrophy (DM) 
cases (two DM type-1 and one DM type-2) and three controls age matched controls.  
3.2 – Animals 
 SAMP8 mice, a model of accelerated aging with memory deficits and amyloid 
deposition, were aged to 11 months of age in accordance with previously described 
husbandry methods (Butterfield and Poon 2005). Husbandry of these mice was performed 
by the lab of Dr. Alan Butterfield’s lab. Isofluorane (4%) anesthetized mice received 
cortical stereotaxic injections of GSK antisense oligonucleotides (GAO; n = 9) or control 
scrambled antisense oligonucleotides (RAO; n = 7) once a week for three weeks. 
Stereotaxic injection coordinates were 0.5 mm posterior to the bregma, 1.0 mm to the 
right of the sagittal suture, and a depth of 2.0 mm. Frozen cortical tissue was 
homogenized in lysis buffer (320 mM sucrose, 1 mM Tris-HCl, 0.098 mM MgCl2, 0.076 
mM EDTA, PIC and PhIC, pH 7.4) with a polytron. Homogenate was centrifuged at 3000 
x g at 4ºC for 5 minutes. The resulting supernatant was then centrifuged at 10,000 x g at 
4ºC for 10 minutes and the supernatant (cytosolic fraction) was transferred to 1.5 mL a 
Eppendorf tube and frozen at -80ºC.  
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3.3 – Western Blot Analysis 
The protein concentrations of the supernatants were measured by BCA protein 
assay (Pierce, Rockford, Illinois). SDS-PAGE samples were prepared in Laemmli sample 
buffer (2% sodium dodecyl sulfate [SDS], 10% glycerol, 62.5 mM Tris-HCL pH 6.8, and 
0.002% bromophenol blue) with 10% β-mercaptoethanol (BME), and heated to 65ºC for 
15 minutes before loading onto a gel. Twenty-five µg protein per sample were loaded 
into 4-12% Bis-Tris Criterion precast SDS-PAGE gels in MOPS running buffer (Bio-
Rad, Hercules, California). The proteins were electrically transferred to 0.2 µm 
nitrocellulose membrane at 1 ampere for 60 minutes. Following transfer the membranes 
were blocked overnight in 1% BSA and 2% BlockAce (AbD Serotec, Raleigh, North 
Carolina) in Tris-Buffered Saline (TBS) at 4ºC. 
 Membranes were incubated for 1 hour in primary antibody diluted in 5% non-fat 
dried milk in Tris-Buffered Saline with 0.1% Tween-20 (TBST), pH 7.4, at room 
temperature. Following 1 hour incubation in primary antibody, blots were rinsed three 
times in TBST buffer for 10 minutes each, then incubated in horseradish peroxidase 
(HRP) conjugated rabbit anti-mouse or donkey anti-rabbit secondary antibodies 
(Rockland Immunochemicals Inc.; Gilbertsville, Pennsylvania, 1:10,000)  diluted in 5% 
non-fat dried milk in TBST for one hour at room temperature on an orbital shaker. 
Following secondary antibody incubation blots were rinsed three times in TBST for 10 
minutes, followed by two rinses in TBS to remove any remaining Tween-20 from the 
membranes. Membranes were then incubated with Super Signal West Dura 
chemiluminescent detection substrate (Pierce, Rockford, Illinois) for 5 minutes, and then 
exposed to autoradiographic film (ISC BioExpress; Fisher Scientific). Films were 
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developed by Kodak X-OMAT 2000A film processor (Eastman Kodak Company, 
Rochester, NY) Films were scanned, and densitometric analysis was performed using 
Image J software (NIH; www.imagej.net). 
Primary antibodies used were as follows:  AT180 (Koike, Green et al. 2010, 
Martinez-Coria, Green et al. 2010, van Eersel, Ke et al. 2010) for pThr-231 tau 
(#MN1040, Pierce, 1:1000), HT7 (Koike, Green et al. 2010, Martinez-Coria, Green et al. 
2010, van Eersel, Ke et al. 2010) for total tau (#MN1000, Pierce, 1:1000), monoclonal 
anti-BIN1 99D (#B9428, Sigma-Aldrich, St. Louis, MO, 1:1000),  rabbit monoclonal 
anti-BACE1 D10E5 (5606S; Cell Signaling, Danvers, MA, 1:1000) and anti-GAPDH 
(ab9385, Abcam; Cambridge, MA, 1:5000). CNBP was detected using an in-house rabbit 
polyclonal antibody (1:5000) (Niedowicz, Beckett et al. 2010).  
3.4 – Recombinant Tau Production and Oligomerization 
Full-length recombinant tau (tau-441 2N4R) was transformed into One Shot® 
Efficiency DH5α-T1R chemically competent E. coli (C6010-03; Life Technologies) 
according to the manufacturer’s instructions and plated on LB agar supplemented with 50 
μg/L carbenicillin (C3416; Sigma-Aldrich). Cells were grown in a shaker at 37ºC 
overnight in 250 mL LB agar. This overnight culture was used to inoculate a new culture 
for protein over expression. Protein expression was induced with 0.5 mM IPTG (I5502; 
Sigma-Aldrich) for 3 hours and then cells were harvested by centrifugation at 2,150 x g at 
4ºC for 10 minutes. The pellet was rinsed in 50 mL of 25 mM Tris-HCl, pH 8.0, and 
centrifuged at 2,150 x g at 4ºC for 10 minutes, the supernatant removed, and the pellet 
frozen at -20ºC.  
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  To purify the expressed tau-441 protein the pellet was resuspended in lysis buffer 
(20 mM MES, 50 mM NaCl, 1 mM MgCl2, 2 mM EGTA, 0.1 mM EDTA, 5 mM DTT, 1 
mM PMSF, 10 µg/mL leupeptin, and 10 µg/mL pepstatin). Cells were lysed by 
sonication by 10 pulses, 0.5 seconds per pulse, at 100 W on ice. NaCl was added to the 
lysate to a concentration of 0.5 M and heated to 95ºC for 10 minutes. The lysate was 
centrifuged at 40,000 x g at 4ºC for 45 minutes. The supernatant was twice dialyzed with 
a cation exchange buffer A (20 mM MES, 50 mM NaCl, 1 mM MgCl2, 2 mM EGTA, 0.1 
mM EDTA, 2 mM DTT, 0.1 mM PMSF) to remove the high concentration of NaCl. 
Cation exchange resin sulfopropyl sepharose 6 was activated with a high salt buffer (100 
mM MES, 1M NaCl, 1 mM MgCl2, 2 mM EGTA, 1 mM EDTA) for one hour, then 
equilibrated with cation exchange buffer A to remove the high concentration of salt. The 
protein was then bound to the resin by rocking the resin with the supernatant at 4ºC for 
one hour. The resin was then washed twice with cation exchange buffer A and loaded 
into a column where it was washed with additional cation exchange buffer A. A linear 
gradient was run against buffer B (20 mM MES, 50 mM NaCl, 1 mM MgCl2, 2 mM 
EGTA, 0.1 mM EDTA, 2 mM DTT, 0.1 mM PMSF, 0.6 M NaCl). Fractions were 
collected and tested by assaying for gel filtration. Briefly, the protein was dialyzed 
against PBS and 1 mM DTT and run on a Superdex 200 gel filtration column at 1 
mL/min. Purified Tau-441 was stored in 20 mM Tris, 100 mM CaCl2, 2 mM MgCl2, and 
1 mM DTT, pH 7.5.  
To induce tau 441 oligomerization DTT was added to purified tau-441 to a 
concentration of 4 mM and incubated at 37ºC for 30 minutes. The solutions were heated 
at 95ºC for 8 minutes. After cooling, DTT was added to a concentration of 1 mM, and the 
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protein concentration was measured by BCA. Tau-441 was incubated in a 1:1 ratio with 
HFIP at 37ºC for 1 hour. Eighty uLs of ddH2O was added to each sample to adjust to a 
final concentration of 2-5 µM per samples and incubated at 37ºC for 1 hour. 
Oligomerized tau samples were then incubated at RT overnight.  
3.5 – Tau Oligomer Toxicity Assay 
 Primary rat hippocampal cultures were treated in duplicate with increasing 
concentrations of tau oligomers (0, 25, 50, and 100 nM, based on total tau concentration). 
Cultures were maintained in a humidified incubator at 37ºC with 5% CO2 with 1.7 mL of 
culture media. 100 uL samples of media were collected at 2, 3, 7, 24, and 48 hour 
timepoints. Media was centrifuged at 250 x g for 5 minutes. LDH activity levels were 
measured using the Cytoscan™-LDH Cytotoxicity Assay Kit (#786‐210; G-Biosciences, 
St. Louis, MO). Briefly, 50 uL of centrifuged media supernatant was added to 50 µL of 
50 µL substrate mix (G-Biosciences) in a 96 well flat bottom plate (#P7366; Nunc; 
Sigma-Aldrich) and incubated at room temperature on an orbital shaker for 30 minutes. 
After 30 minutes stop solution (G-Biosciences) was added and the absorbance of each 
well was measured at 490 nm.  
 SH-SY5Ys were treated similarly with some minor changes. Cells were grown in 
96 well tissue culture plates in DMEM with 10% FBS and 1% PS. Once the cells reached 
~70% confluence they were treated with varying concentrations of tau oligomers (0, 10, 
50, 100, and 200 nM, based on total tau concentration). Six control wells containing cells 
were left untreated for each timepoint. At 24, 48, and 72 hours 3 untreated wells were 
lysed with Lysis Solution (G-Biosciences) to use as controls representing maximum cell 
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death. The plates were centrifuged at 250 x g for 5 minutes and 50 uL of the supernatant 
was transferred to a fresh 96 well plate. Fifty uL of fresh media were added to 6 empty 
wells of the 96 well plate to use as spontaneous controls. Fifty uL of substrate mix (G-
Biosciences) was added to each well and the plate was incubated for 30 minutes at room 
temperature on an orbital shaker. After 30 minutes stop solution (G-Biosciences) was 
added and the absorbance of each well was measured at 490 nm. The median absorbances 
from lysed wells (Maximum LDH Release) and fresh media containing wells 
(Spontaneous) were used in cytotoxicity calculations. Percent cytotoxicity was 
determined using the following formula: ((Experimental (OD490) – Spontaneous (OD490)) 
/  Maximum LDH Release (OD490)) x 100.  
3.3 – RESULTS 
3.3.1 – GSK3β Knock-Down Reduces Tau Phosphorylation 
Many studies have tried to reduce GSK3β activity with pharmacologic inhibitors, 
such as lithium (Engel, Goni-Oliver et al. 2006). Lithium and other inhibitors, however, 
have many mechanisms of action; therefore we specifically knocked-down GSK3β 
expression using antisense olgionucelotide technology in the cortex of SAMP8 mice 
(Figure 3.1). Overall, a significant reduction of tau phosphorylation was observed at the 
threonine-231 (AT180) epitope in SAMP8 mice treated with the GSK3β antisense 
oligonucleotides compared to random antisense oligonucleotide treated animals (p ≤ 
0.05). This suggests that direct reduction in GSK3β can reduce pathological T231 
hyperphosphorylation associated with tauopathies.  
41 
 
3.3.2 – Protein Expression in Myotonic Dystrophy (DM)  
 To determine how DM mechanisms may alter expression of AD related proteins 
we obtained a small set of human samples and probed them by western blot. As expected 
we observed striking differences in tau protein in DM cases compared to controls, with 
different banding patterns indicating differential isoform expression, likely due to 
disrupted splicing mechanisms (Figure 3.2). Additionally, total levels of tau were 
significantly reduces as determined by densitometric analysis (p ≤ 0.01). BACE1, which 
is involved in amyloidogenic processing was significantly increased compared to controls 
(p ≤ .01). Bridging Integrator 1 (BIN1), which has been implicated to be a major genetic 
locus associated with AD susceptibility, trended to be expressed at higher levels 
compared to controls (p ≤ 0.08)(Harold, Abraham et al. 2009, Lambert, Heath et al. 2009, 
Seshadri, Fitzpatrick et al. 2010). Expression of CNBP was also significantly increased 
compared to controls (p ≤ 0.01). The increase in CNBP expression is of note, as ZNF9, 
the gene which codes for CNBP, is implicated in DM2, but the altered expression 
observed in DM1 cases indicates it likely plays a larger role in the disease process. 
3.3.3 – Tau Oligomers are Highly Cytotoxic 
 To determine the impact of different tau assemblies and conformational structures 
on cell viability we treated SH-SY5Y neuroblastoma cells with tau monomers, fibrils, 
and oligomers. Toxicity, as measured by LDH release, was only detected upon 
oligomeric tau treatment (Figure 3.3A; p ≤ 0.05). Tau oligomers have been implicated as 
the most toxic tau species. Primary rat neurons cultured from the hippocampus and SH-
SY5Y cells were treated with increasing concentrations of tau oligomers. LDH activity 
was then measured as a marker of cytotoxicity from the media of these cells. Primary 
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neurons were treated in duplicate as we were limited by the number of plates we could 
use, but a clear rise in LDH activity was detected (Figure 3.3B). SH-SY5Y cells treated 
with oligomers display significantly higher levels of LDH activity over time (p ≤ 0.001), 
with 35% cytotoxicity measured with 200 nM tau oligomers at 48 hours post treatment 
(Figure 3.3C; p ≤ 0.001). These data indicate that tau oligomers are highly cytotoxic to 
both primary neurons and cultured cell lines.  
3.3.4 – Pathology in Human Diabetic and AD Cases 
As T2DM has been associated with increased risk of dementia we wanted to 
determine if AD patients with T2DM developed more severe pathology than non-diabetic 
AD patients. We analyzed neuropathology data from control, diabetic, AD, and diabetic 
AD cases acquired from the Sanders-Brown neuropathology core (Table 3.1). 
Interestingly, diabetic AD cases displayed significantly reduced tangle counts throughout 
the brain (except in the occipital lobe) compared to non-diabetic AD cases (Figure 3.4; 
Frontal: p ≤ 0.001, Temporal: p ≤ 0.001, Parietal: p ≤ 0.005, Amygdala: p ≤ 0.001, 
Entorhinal Cortex: p ≤ 0.001, Hippocampus: p ≤ 0.001, Subiculum: p ≤ 0.001; n = 
13M/16F control, 17M/12F diabetic, 9M/20F AD, 13M/15F diabetic AD). By contrast, 
comparison of the occurrence of neuritic and diffuse plaques in the same cases revealed 
no significant difference between brain regions (data not shown).  
3.4 – DISCUSSION  
 To date there are approximately two dozen neurodegenerative diseases classified 
as tauopathies (Delacourte and Buee 2000, Lee and Leugers 2012). Each of these 
diseases presents tau pathology in different ways, some develop NFTs in specific areas of 
the brain and others accumulate in different structural conformations of high order tau 
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aggregates. The mechanisms which drive each of these tauopathies are similar, some of 
these mechanisms are distinctive, yet many others are involved in multi-pathway 
crosstalk and may occur as a result of a variety of other pathologies. 
  It is also interesting to note that while most discussions about tau focus on the 
development of tau aggregates and disruption of the microtubule network, tau has many 
other functions aside from cytoskeletal stabilization. Tau has been shown to associate 
with nucleoli and polysomes, and mutations in tau may result in chromosomal 
abnormalities (Loomis, Howard et al. 1990, Thurston, Zinkowski et al. 1996, Rossi, 
Conconi et al. 2014). Certain phosphorylation events cause tau to interact with cellular 
membranes, and tau may interact with lipid raft components involved in growth cone 
function in oligodendrocytes (Maas, Eidenmuller et al. 2000, Klein, Kramer et al. 2002). 
Tau may not only have a role inside the cell, but also outside; a recent study has 
implicated AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor)-
induced synaptic release of tau (Pooler, Phillips et al. 2013).  Additionally, extracellular 
tau has been shown to increase intracellular calcium concentrations in primary 
hippocampal and cortical neurons (Gomez-Ramos, Diaz-Hernandez et al. 2008).  
In summary, the data in this chapter indicate that tau pathogenesis in tauopathies 
and subsequent neurodegeneration is highly varied and there may be many mechanisms 
which contribute to the development of disease. Additionally, mechanisms which 
promote tauopathy are likely also involved in the development of amyloid pathology. 
Subsequent chapters explore one potential mechanism associated with metabolic 
dysregulation. 
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 Table 3.1 Human Subject Demographic Data 
     
  
Sex, M/F 
(no.) 
Age 
(years)* 
PMI 
(hours)* 
Braak Stage 
(Median) 
Control 13/16 82.1 ± 1.1 5.0 ± 1.0 II 
Diabetic 17/12 82.1 ± 1.2 4.0 ± 0.6 II 
AD 9/20 82.1 ± 1.2 7.4 ± 1.0 VI 
Diabetic 
AD 
13/15 82.2 ± 1.2 3.9 ± 0.5 VI 
     
 
* Values are given as mean ± SEM 
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Figure 3.1 Antisense Oligomer Knockdown of GSK Reduces Total GSK3β Levels 
and Tau Phosphorylation in SAMP8 Mice. 
GAO-treated (n = 9) SAMP8 mice displayed decreased GSK3β expression (A&B) and tau 
phosphorylation (C) compared to RAO-treated mice (n = 7; t-test, * = p≤0.05). Shown are 
two representative western blots of samples from each group and of GAPDH (loading 
control). 
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Figure 3.2 Altered Protein Expression in the Frontal Cortex of Myotonic Dystrophy 
Homogenates. 
(A) CNBP, BACE1, and Tau (note also the different pattern of Tau isoforms in DM 
cases; the two DM1 cases were essentially indistinguishable from the single DM2 case, in 
the last lane) increase in the frontal cortex of DM cases relative to age-matched controls 
(BIN1, 99D, Sigma; Tau, Tau46, Cell Signaling; BACE1, 5606, Cell Signaling; βActin, 
AC15, Sigma); CNBP antibody, per [24]). (B) Quantification of DM cases / controls (t-
test, * = p≤0.05, ** = p≤0.01, *** = p≤0.001; (*) = p≤0.08).  
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Figure 3.3 Oligomeric Tau is Toxic to Primary Rat Neurons and Human SH-SY5Y 
Neuroblastoma Cells. 
(A) Monomeric, fibrillar, and oligomeric tau were administered to SH-SY5Y cells. Only 
oligomeric tau was cytotoxic by LDH assay (ANOVA, p ≤  0.05). (B) LDH activity (a 
marker for cell death) increases in rat hippocampal neurons in a dose dependent manner 
with oligomeric tau concentrations. This response can be seen from the earliest timepoint 
of two hours and is sustained up to 48 hours. (C) Increasing the concentration of 
oligomeric tau treatments in SH-SY5Y cells revealed concentrations of 50 nM or higher 
significantly increase cytotoxicity at 48 hours (ANOVA, * p ≤ 0.01, ** = p≤0.001).  
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Figure 3.4 NFT Counts are Reduced in Diabetic AD Cases Compared to Non-
Diabetic AD Cases. 
When comparing tangle counts in human cases, diabetic AD cases displayed significantly 
reduced tangle counts throughout the brain (except in the occipital lobe) compared to 
non-diabetic AD cases (n = 13M/16F control, 17M/12F diabetic, 9M/20F AD, 13M/15F 
diabetic AD).  
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CHAPTER 4: Diabetes, Obesity, and Neurodegeneration 
Portions of this chapter are reprinted with permission from: 
Niedowicz DM, Studzinski CM, Weidner AM, Platt TL, Kingry KN, Beckett TL, Bruce-
Keller AJ, Keller JN, Murphy MP (2013). Leptin regulates amyloid β production via the 
γ-secretase complex. Biochem Biophys Acta. 2013 Mar;1832(3):439-44 
Niedowicz DM, Reeves VL, Platt TL, Kohler K, Beckett TL, Powell DK, Lee TL, Sexton 
TR, Song E, Brewer LD, Latimer CS, Kraner SD, Larson KL, Ozcan S, Norris CM, 
Hersh LB, Porter NM, Wilcock DM, Murphy MP (2014) Obesity and Diabetes Cause 
Cognitive Dysfunction in the Absence of Accelerated Beta-Amyloid Deposition in a 
Novel Murine Model of Mixed or Vascular Dementia. Acta Neuropathologica 
Communications. 2014 Jun; 2(64) 
4.1 – INTRODUCTION  
 The development of AD, the most common neurodegenerative disease associated 
with age, can be driven by many factors including genetic, vascular, and metabolic  risks 
(Peila, Rodriguez et al. 2002). While cases with direct familial contribution to disease 
pathogenesis do occur, it is rare. A majority of AD cases are classified as sporadic, with 
no clear insult or factor giving rise to the disease state. In the last quarter century the 
scientific community has shed some light on risks which may increase the risk for AD, 
including mid-life obesity, metabolic syndrome, and diabetes (Gustafson, Rothenberg et 
al. 2003, Whitmer, Gunderson et al. 2005, Wolf, Beiser et al. 2007).  
 As obesity levels have risen to an epidemic level, there is increasing concern that 
peripheral effects associated with obesity may impact the development of other 
pathologies, including AD (Bray 2004). Mid-life obesity is a driving factor associated 
with dementia, with one study demonstrating that obese individuals have a two-fold 
increased risk of developing dementia than normal weight individuals (Kivipelto, Ngandu 
et al. 2005). Interestingly, a related study with similar findings demonstrated that patterns 
of fat deposition also displayed relationship with the development of dementia, as 
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individuals in the top fifth distribution of skin fold thickness in the subscapular or tricep 
regions has a 72% and 59% increased risk of dementia, respectively (Whitmer, 
Gunderson et al. 2005). T2DM, which is highly associated with obesity, is commonly 
cited as a likely cause of pathogenesis in these diseases (Luchsinger and Mayeux 2007). 
Several studies have demonstrated that T2DM imparts an increased risk of developing 
AD, while findings related to the severity of pathology are controversial (Janson, Laedtke 
et al. 2004, Xu, Qiu et al. 2004, Haan 2006). Interestingly, most studies solely focus on 
insulin-resistance as the key mechanism by which pathogenesis is initiated when studying 
obesity, T2DM, and dementia. While it is undeniable that the effects of insulin-resistance 
are wide reaching, there are other dysfunctional signaling events found to be associated 
with chronic obesity. Impaired leptin signaling is one such mechanism. 
Leptin is a peptide hormone which is secreted from adipose tissue, proportionally 
with the amount of stored adipose. Leptin is secreted from adipose tissue to regulate 
satiety and energy expenditure via the hypothalamus. However, the leptin receptor (Ob-
R) is expressed throughout various other regions of the brain, which suggests it likely 
plays another role outside metabolic regulation (Couce, Burguera et al. 1997, Shioda, 
Funahashi et al. 1998, Burguera, Couce et al. 2000). Leptin signaling classically regulates 
transcription via Janus Kinase – Signal Transducer and Activator of Transcription (JAK-
STAT) pathways (Hakansson and Meister 1998, Elias, Aschkenasi et al. 1999, Munzberg, 
Huo et al. 2003). However, leptin signaling also involves a variety of other signaling 
cascades including the PI3K/AKT and MAPK pathways (Figure 4.1) (Banks, Davis et al. 
2000, Bjorbaek, Buchholz et al. 2001, Niswender, Morton et al. 2001, Zhao, Huan et al. 
2002, Rahmouni, Haynes et al. 2003, Cota, Proulx et al. 2006, Cota, Matter et al. 2008). 
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Elevated leptin signaling has also been shown to improve cognition in rodents and 
humans, and has been correlated with a decreased risk of dementia and AD (Harvey 
2007, Lieb, Beiser et al. 2009, Greco, Bryan et al. 2010). Individuals who are obese, and 
often suffer from T2DM as a result of obesity, develop resistance to leptin signaling over 
a long period of time (Campfield, Smith et al. 1995, Halaas, Gajiwala et al. 1995, 
Considine, Sinha et al. 1996, Ostlund, Yang et al. 1996).  
 In this chapter, we explore the effects of leptin signaling and leptin resistance in 
cell culture and in vivo. We demonstrate that leptin signaling inhibits the generation of 
Aβ and negatively regulates the expression of γ-secretase components. Furthermore, we 
outline characteristics of a novel mouse line combining AD pathology (APP/PS1 knock-
in mice) and a leptin-resistance induced model of obesity and diabetes. We demonstrate 
that while these mice develop cognitive impairments, this impairment is induced not by 
increased Aβ deposition, but rather by the development of vascular pathology. Taken 
together, these results indicate that leptin resistance, obesity, and diabetes are key factors 
which enhance neurodegenerative properties of AD mice.  
4.2 – METHODS  
4.2.1 – Animals 
 For the initial diet study, APP
KM670/671NL 
x PS1
P264L
 knock-in mice (CD-1/129 
background; hereafter referred to as ‘AD’ mice) were fed a control (20% fat, n = 46), 
western (40% fat, n = 14), or ketogenic (80% fat, n = 47) diet ab libitum (Research Diets, 
New Brunswick, NJ) for one month (n= 37 wild type, 49 heterozygotes, 21 homozygotes; 
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Gender: n = 52 males, 55 females). At the end of the feeding period mice were 
euthanized and brain and plasma were collected for analysis.  
 To generate the db/AD line the Lepr
db/db
 mice (C57Bl/6 J background; (Jackson 
Labs; Bar Harbor, Maine; referred to as db mice) were crossed with the AD mouse line. 
db
+/-
 mice (as db
-/-
mice are infertile) were crossed with homozygous AD mice. F1 
heterozygotes (db
+/-
 and AD
+/-
) were then used to generate the colony for all studies. The 
majority of experiments outlined focus on four main genotypes: db
+/+
 x APP
+/+
/PS1
+/+
 
(wt/wt), db
-/- 
x APP
+/+
/PS1
+/+
 (db/wt), db
+/+ 
x APP
KM670/671N/
/PS1
P264L
 (wt/AD), and db
-/-
 x 
APP
KM670/671NL
/PS1
P264L
 (db/AD). All husbandry for this cohort was performed by the 
Murphy lab.   
4.2.2 – Plasma Leptin and Aβ ELISAs 
Plasma was collected as previously described in chapter 2. Plasma leptin was 
measured using a commercially-available ELISA kit according to manufacturer’s 
methods (#EZML-82K, Millipore). For Aβ ELISAs, tissue was serially extracted in PBS, 
then 2% SDS, and finally 70% formic acid (FA). All extraction buffers were 
supplemented with PIC and, when looking at phospho-tau, PhIC. Briefly, extracts were 
diluted in PBS homogenization buffer (1 mL buffer per 200µg sample) and homogenized 
with a polytron. Homogenate was centrifuged at 20,800 x g for 30 minutes at 4ºC and 
supernatants stored at -80ºC. Pellets were resuspended 0.7 mL 2%SDS, and sonicated (10 
x 0.5 sec. at 100 W) followed by centrifugation at 20,800 x g for 30 minutes at 14ºC to 
prevent SDS from precipitating. Supernatants were frozen at -80ºC. The remaining pellet 
was then extracted with 70% FA by sonication and centrifugation at 20,800 x g for 60 
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minutes at 4ºC. PBS and SDS extracts were diluted in AC buffer (0.2 M Na3PO4, 0.4 M 
NaCl, 2 mM EDTA, 0.4% Block Ace, 0.4% BSA, 0.05% CHAPS, 0.05% NaN3) before 
analysis used to perform a standard sandwich ELISA in 384 well plates, using Ab42.5 as 
the capture antibody and biotinylated-4G8 antibody for detection. Following 4G8 
incubation, plates were incubated with 0.1% NeutrAvidin-HRP (Pierce) and developed 
with 3’,3’,5’,5’-tetramethylbenzidine (TMB) and stopped with 6% phosphoric-acid. 
Absorbance of each well was measured at 450 nm. 
4.2.3 – Immunoblots 
 For western blot analysis, samples were processed as described for ELISAs or by 
RIPA extraction as previously described. Protein samples were run on Bis-Tris Criterion 
precast SDS-PAGE (4-12% gradient) gels in MOPS running buffer (Bio-Rad). The 
proteins were electrically transferred to 0.45 µm or 0.2 µm nitrocellulose membrane at 1 
ampere for 60 minutes. For dot blots, 1 µg sample per well was transferred to 0.45 µm 
nitrocellulose membrane by vacuum manifold. Membranes were blocked overnight in 1% 
BSA and 2% BlockAce at 4ºC. The following protein-specific antibodies were used to 
determine protein expression: AT8 (Hu, Waring et al. 2008, Greco, Sarkar et al. 2009, 
Martinez-Coria, Green et al. 2010) for pSer-202/Thr-205 tau (#MN1020, Pierce, 1:1000), 
HT7 for total tau (#MN1000, Pierce, 1:1000), CT20 for APP (1:1000),  and anti-GAPDH 
(ab9385, Abcam; 1:5000) and anti-Actin (A1978, Sigma; 1:5000) were used to 
standardize protein expression. 
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4.2.4 – qPCR 
 RNA was isolated from brain tissue and cultured cells by homogenization in 
Trizol™ (#15596-026, Invitrogen) followed by phenol/chloroform extraction and 
purification using RNeasy columns (#74106, Qiagen; Valencia, California). γ-secretase 
components, BACE1, and BACE2 mRNA levels were measured by two-step qRT-PCR 
with iScript (#170-8890, Bio-Rad) for reverse transcription, and PerfeCTa FastMix™ 
(Quanta; Gaithersburg, Maryland) for the qPCR reaction. The geometric mean of the CT 
values for 18S rRNA, β-actin, and GAPDH was used as an internal control to calculate 
and compare relative expression (2-
∆∆C
T). Gene-specific primer sets were obtained from 
IDT (Coralville, IA) and the sequences are presented in Table 4.1.  
4.2.5 – Histology 
 A set of fixed hemibrains (in 10% formalin) were processed by NeuroScience 
Associates (Knoxville, Tennessee), in which hemibrains were embedded in a matrix and 
cut at a thickness of 30 microns. Total Aβ was stained using the 4G8 antibody. For 
Prussian Blue staining (staining of hemosiderin) another set of fixed hemibrains were 
paraffin imbedded and sectioned at a thickness of eight microns and mounted to slides. 
Tissue was deparaffinized, and hydrated before staining in a solution of 2% K₄[Fe(CN)₆] 
and 2% hydrochloric acid. Sections were rinsed in H2O and counter-stained with neutral 
red. Finally, sections were rinsed, dehydrated with ethanol, cleared with SafeClear™ 
(#23-314-629, Fisher Scientific), and then coverslipped.  
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4.2.6 – MRI 
 Dr. David Powell of the UKY Magnetic Resonance Imaging and Spectroscopy 
Center assisted us in acquiring MRI scans of living mouse brains. T2*-MRI was 
performed by a horizontal bore Bruker Clinscan (7.0T, 30 cm, 300 MHz: Billerica, MA) 
imager equipped with a triple-axis gradient (630 mT/m and 6300 T/m/s) and a helium-
cooled 14K quadrature head cryo-coil, cooled to 20°K. T2*-weighted images were 
acquired with a 2D GRE sequence with at 34 µm x 34 µm x 400 µm resolution, 15mm 
FOV, 25 degree flip angle, 10 averages, TR 165ms, and TE 15.3ms. Mice were 
anesthetized with isofluorane and temperature and respiration were constantly monitored 
throughout imaging. Ten or more equally spaced images were acquired over the course of 
imaging.  
4.2.7 – Vascular Corrosion Casting and Scanning Electron Microscopy 
 Mice were anesthetized using 100 mg/kg pentobarbital and transcardially 
perfused with heparinized 0.9% saline, followed by 4% para-formaldehyde. With the help 
of Dr. Nada Porter and her lab, brains were perfused with a polyurethane resin (Pu4ii, 
VasQtec; Zurich, Switzerland) at a rate of 4 mL per minute. The resin was allowed to 
cure for two days, followed by a 48 hour incubating in 7.5% KOH at 50ºC. Brains were 
then incubated for 24 hours in 5% formic acid at 50ºC. Tissue was then frozen and 
lyophilized to macerate the tissue. Casted brains were sputter-coated in palladium and 
imaged by scanning electron microscopy (Hitachi S-4200; Schaumburg, Illinois). 
Endothelial cell density was determined by endothelial cell nuclear imprints measured 
directly using Image J software. Aneurysm pathology was assessed on a 4 point scale 
based on clear data break points (0 = none; 1 = 1 possible; 2 = 1-3 definite; 3 = 4+ 
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definite. Vascular density was determined by rank order of representative images using 
three blinded, independent reviewers. Images were scored from 1 (most dense) – 26 (least 
dense), and the ranks from the three reviewers averaged. 
4.3 – Results  
4.3.1 – Leptin Reduces Total Aβ Production 
  In a previous diet study, examining the impact of high fat consumption on Aβ 
production in AD mice, we observed that mice with higher plasma leptin levels had 
decreased levels of total Aβ in the brain (p ≤ 0.0001, n = 37 wild type, 49 heterozygotes, 
21 homozygotes; Figure 4.1). Diet in this study had no effect on total Aβ production (p = 
0.66) but did significantly increase plasma leptin levels (p = 0.02), suggesting that 
increases in plasma leptin concentrations were the likely cause of reduced Aβ generation. 
 To further examine the effects observed in mice, we treated human H4 
neuroglioma cells overexpressing APP
KM670/671NL
 with 0, 10, and 50 ng/mL leptin diluted 
in cell culture media. Expression of total Aβ was reduced in a dose dependent manner in 
response to leptin (p = 0.024, Figure 4.2A), supporting the observations made in AD 
mice. Western blot analysis of APP expression revealed an increase in αCTF expression 
at higher concentrations of leptin (Figure 4.2B). This observation was indicative that the 
second cleavage event of APP by the γ-secretase complex was in some way inhibited by 
leptin treatment, resulting in an increase of αCTFs (Zhao, Chen et al. 1999).  
 To determine if reduced processing of αCTFs by the γ-secretase complex is due to 
direct inhibition of the complex or by reduced expression of γ-secretase components we 
measured mRNA expression of γ-secretase subunits in leptin treated APPKM670/671NL 
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overexpressing H4 neuroglioma cells (Figure 4.3). The γ-secretase complex is composed 
of four major subunits: presenilin (PS), nicastrin, presenilin enhancer 2 (PEN-2), and 
anterior pharynx-defective 1 (APH-1) (Kaether, Haass et al. 2006). PS acts as the 
catalytic subunit through its aspartyl-protease activity, nicastrin and APH-1 bind to PS 
and stabilize the complex, and PEN-2 activates PS (Watanabe, Tomita et al. 2005). All of 
these components are critical to the proper function of the γ-secretase complex. Leptin 
treatments at a concentration of 50 ng/mL significantly reduced mRNA expression of all 
γ-secretase components (p ≤ 0.03). Interestingly, the PS2 isoform displayed no alterations 
in expression, and BACE2 expression increased with leptin treatment (p = 0.004). 
Collectively, these data suggest leptin signaling reduces the expression of the γ-secretase 
complex, therefore inhibiting γ-secretase processing of APP CTFs.  
4.3.2 – Characteristics of the db/AD Mouse 
 In cases of chronic obesity and diabetes plasma leptin levels remain high for long 
periods of time (Considine, Sinha et al. 1996). Due to these chronically high levels of 
leptin, a resistance to leptin signaling develops (Bjorbaek, El-Haschimi et al. 1999). 
Therefore we proposed to explore the effects of leptin resistance, obesity, and diabetes on 
AD pathogenesis. We crossed the db line, which is leptin resistant due to a mutation in 
the leptin receptor gene, with the AD knock-in mouse line to produce the db/AD mouse. 
Mice homozygous for the db mutation (db
-/-
) developed morbid obesity in both females 
and males (p ≤ 0.001 for all ages; Figure 4.4A-B). Heterozygotes (db+/-) did not display 
any significant weight gain compared to wild type (db
+/+
) mice. The AD genotype did not 
significantly affect body weight (p ≤ 0.3 for all ages). Glucose tolerance was significantly 
impaired in mice homozygous for the db genotype (p≤0.0001 for the db genotype overall, 
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n=14 WT; 13 db; 30 AD; 18 db/AD; Figure 4.4C-D). Similar results were observed in 
insulin tolerance tests, where mice homozygous for the db genotype displayed significant 
impairment in response to insulin (p≤0.0001 for the db genotype overall; n=14 WT; 13 
db; 30 AD; 18 db/AD; Figure 4.4E-F). Together this data indicates that db homozygotes 
are morbidly obese and have severe metabolic dysfunction compared to wild type and 
heterozygous littermates.  
4.3.3 – db/AD Mice Display Cognitive Deficits 
 To determine if the diabetic phenotype had any influence on cognitive function, 
mice were tested by a MWM. Over the course of five days mice of the four genotypes 
were trained and after the trials on the fifth day underwent a probe trial. Though no 
differences were observed on the first day, as the week went on the db/AD mice had 
significantly longer path lengths compared to the other genotypes (p ≤ 0.05 for days 2-5), 
suggesting that these mice displayed cognitive impairment (Figure 4.5A). In the probe 
trial db/AD mice spent less time in the target quadrant (p ≤ 0.04) and target zone (p ≤ 
0.01; Figure 4.5B). These data indicate that the convergence of the db and AD genotypes 
produce a phenotype, unique from the parental lines, which results in cognitive deficit. 
4.3.4 – db/AD Mice Do Not Display Increased Aβ Deposition 
 As previous data indicated leptin signaling inhibits γ-secretase expression, we 
expected complete leptin resistance would increase expression and activity of the γ-
secretase complex, resulting in an increase in total Aβ. With the cognitive deficits 
observed in db/AD mice, we expected increased Aβ levels. Using IHC we visualized Aβ 
deposition (4G8) in the brains of mice from all four genotypes. Both AD and db/AD mice 
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displayed positive staining for Aβ (Figure 4.6A). Interestingly, plaque deposition did not 
seem higher in db/AD mice, as was predicted. Analysis of total Aβ levels from the brains 
of young 6-7 month old and older12 month old mice indicated total Aβ levels increase 
with age in AD and db/AD  mice (p ≤ 0.0001, age: [6mo/12mo] n = 13/8 WT, 13/8 db, 9/8 
AD, 11/7 db/AD; Figure 4.6B). However, db/AD mice did not display increased total Aβ 
concentrations compared to AD mice as was expected.    
4.3.5 – db/AD Mice Display Vascular Pathology 
 The cognitive deficits observed in db/AD mice are not due to increased plaque 
burden over other genotypes. To better explore the underlying mechanisms which cause 
these cognitive deficits in db/AD mice we analyzed the structure of the 
cerebrovasculature. Vascular corrosion casting with a polyurethane resin was used to 
create casts of the brain vasculature which were analyzed by SEM. Vasculature of WT 
and db mice appeared normal (Figure 4.7A). Both AD and db/AD mice, however, 
displayed extensive cerebrovascular pathology, ranging from slight blebbing of vessels 
(Figure 4.7B), extensive aneurysms along individual vessels (Figure 4.7C), to highly 
complex saccular aneurysms (Figure 4.7D). While this pathology was extensive it did 
not explain the cognitive deficits which were only observed in db/AD mice.  
To determine if the vascular pathology observed by SEM could be indicative of 
stroke pathology mice were subjected to scanning by small animal MRI. Almost 
exclusively db/AD mice displayed evidence of some vascular events (11/15 db/AD mice; 
Figure 4.8A-C), whereas only two (2/9) AD (Figure 4.8F) mice displayed any evidence, 
and no WT (0/9; Figure 4.8D) or db (0/10; Figure 4.8E) mice displayed any signs of 
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vascular event (Figure 4.8). Brain sections from scanned mice were stained with Prussian 
blue (which stains ferric deposits blue) with a neutral red counter-stain and regions which 
tested positive for vascular event were examined for evidence of bleeding. Sections 
showed no evidence of hemorrhagic event, yet dense clusters of neutral red staining 
suggests these are likely ischemic strokes (Figure 4.9A-D). Extensive analysis of stained 
sections did reveal some signs of microbleeds, but this was a rare occurrence (Figure 
4.9E-F).  
4.4 – Discussion 
 The combination of the db and AD genotypes imparts a unique phenotype which 
is not observed in either parental line. Interestingly, though our hypothesis suggested 
leptin resistance would result in increased neurodegeneration through amyloid pathology, 
we did not observe increased generation or deposition of Aβ in the brains of these mice. 
Instead, pathological hallmarks of vascular disease were apparent. Experiments described 
in this chapter suggest metabolic dysfunction, as result of leptin resistance, obesity, and 
diabetes, exacerbate cerebrovascular pathology found in AD mice, resulting in cognitive 
impairment.  
 Our results indicate that increased plasma leptin levels inhibit the generation of 
Aβ through inhibition of γ-secretase complex expression, which we also observed in cell 
culture. This supports previous observations made by Lieb et al. where individuals with 
higher plasma leptin concentrations were less likely to develop dementia or AD over the 
course of the study (Lieb, Beiser et al. 2009). These data do not, however, provide clear 
65 
 
indication as to whether or not secondary mechanisms involved in leptin signaling may or 
may not impact activity of β-secretase, and requires further study.  
 Translation of these findings into the clinical setting, however, will be highly 
challenging. Upon discovering the function of leptin, our basic understanding of energy 
metabolism and weight homeostasis was greatly expanded. Scientists believed leptin 
would be a breakthrough in anti-obesity therapies, and would herald in a new generation 
of weight loss pharmaceuticals. Leptin therapies in humans, however, proved fruitless, as 
weight loss resulting from leptin treatments was marginal at best (Heymsfield, Greenberg 
et al. 1999).  It was soon discovered that chronically elevated levels of circulating leptin 
triggers mechanisms which result in decreased or resistant leptin signaling (Martin, Perez 
et al. 2000, Banks and Farrell 2003, Munzberg, Flier et al. 2004). This realization dashed 
any real hopes that leptin alone could be used as a pharmaceutical intervention for 
obesity. 
 It is these previously encountered obstacles involved with leptin therapeutics 
which led us to study the effects of leptin resistance, and resulting obesity and T2DM, on 
AD pathogenesis. The Lepr
db
 line was ideal to create a mouse model to study these 
effects. The mutation in the leptin receptor gene results in a mis-spliced variant of the 
mRNA product with a pre-mature stop sequence. This generates a truncated peptide 
which can no longer initiate any signaling events, and because of this, it perfectly imitates 
leptin resistance (Chen, Charlat et al. 1996). Additionally, the Lepr
db
 line is inherently 
sickly, and the hybrid generated by crossing it with the AD line is more robust, allowing 
for better description of the aged phenotype.  
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 The resulting db/AD mice display the same metabolic phenotype as the parental 
Lepr
db
 line. db homozygotes weigh more than control littermates from birth and quickly 
develop morbid obesity. The phenotype is so extreme that often the genotype of 
homozygotes can be determined simply based upon the appearance of the mice, before 
genotypic analysis. These mice are insulin intolerant and display severely impaired 
glucose handling at a young age. Due to their morbid obesity, db homozygotes developed 
secondary complications. With their inability to properly groom db mice often developed 
dermatitis, urine scald due to excessive urination, and genital impaction of cage litter. 
Because of these conditions the cage litter was changed to a soft absorbent litter and 
cages were changed every other day.  Interestingly, we also observed a group of db/AD 
mice from each generation, primarily males, would mysteriously begin losing weight 
between three and six months then spontaneously die. Overall, the obese and diabetic 
phenotypes of this line were exactly what we were aiming for in developing this line.  
 Contrary to our hypothesis, db/AD mice developed no more extensive amyloid 
deposition than AD mice. This finding was quite surprising, as other studies in our lab 
have demonstrated PS1 expression was increased in db/AD mice, just as expected 
(Niedowicz, Reeves et al. 2014). The same study also showed that none of the major Aβ 
clearance enzymes (insulin degrading enzyme, neprilysin, and endothelin converting 
enzyme) were elevated nor were peripheral or vascular Aβ levels elevated, suggesting 
that clearance of excess Aβ is not a likely culprit for normal Aβ levels.  
 More confounding was the observation that db/AD mice display cognitive 
impairment in the MWM. It is known that AD mice develop cognitive impairment at 
much older ages, yet do not at the age tested in this study (Webster, Bachstetter et al. 
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2013). The finding that db/AD mice were the only genotype which did display impaired 
cognition suggests that crossing the db and AD produces new pathologic phenotype. 
Vascular corrosion casting of the brain revealed vascular abnormalities in both AD and 
db/AD genotypes, suggesting these genotypes develop severe aneurysm pathology. MRI 
analysis further revealed that db/AD mice develop many small strokes, which are 
predominately ischemic based on histological analysis.  
While aneurysms are associated with both AD and db/AD mice, it is interesting 
that crossing of the db and AD lines is required to produce stroke pathology. As no 
increases in amyloid deposition or generation were observed it is unlikely that Aβ 
promotes the occurrence of these ischemic events. Previously observed increases in γ-
secretase expression in db/AD mice could instead be the causative factor (Niedowicz, 
Reeves et al. 2014). PS has been implicated to be involved in angiogenic signaling via 
Notch signaling pathways (Lukiw, Gordon et al. 2001, Nakajima, Yuasa et al. 2003). 
Alterations in angiogenesis in combination with cerebrovascular abnormalities observed 
in mice with the AD genotype may weaken vessel walls, resulting in stroke pathology. 
This, however, does not take into account the many other pathologic conditions 
associated with obesity and diabetes. Intracerebroventricular injection of STZ in non-
transgenic mice, a common model of brain insulin resistance and sporadic AD, causes 
severe cognitive deficits, which supports the notion that dysfunctional insulin signaling 
may be involved in neurodegenerative disease (Salkovic-Petrisic and Hoyer 2007, Chen, 
Liang et al. 2013). STZ-induced diabetes in the hAPP AD model increases amyloid 
plaque deposition, tau phosphorylation, and cognitive impairment (Jolivalt, Hurford et al. 
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2010). So while altered PS expression explains the vascular pathology observed in our 
model, effects resulting from metabolic dysfunction in this line warrant further study.  
Overall, we have shown in this chapter that we have generated a mouse line with 
leptin resistance, obesity, and diabetes in combination with AD pathology. This line 
develops cognitive dysfunction due to vascular pathology and not amyloid pathology as 
expected. Interestingly both AD and db/AD mice develop aneurysms, yet only in db/AD 
mice are ischemic events observed in addition to aneurysm pathology. These exciting 
results leave us with more questions and another aspect of the disease to explore: tau 
pathology.  
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Table 4.1 qPCR Primers.  
 
Target 
Gene Direction Sequence 
PS1 
forward 5′-AAATGGGTGCTTTGTGGTCTCTGC-3′ 
reverse 5′-CAGGCTGATGGCTGTTTGTGTGTT-3′ 
PS2 
forward 5′-ATGGACAGCTCATCTACACGCCAT-3′ 
reverse 5′-AGAGCACCACCAAGAAGATGGTCA-3′ 
PEN2 
forward 5′-TCTCGCGCAAACGTCCATAACTGA-3′ 
reverse 5′-AATGGACACTCGCTCCAGGTTCAT-3′ 
Nicastrin 
forward 5′-AGTGCCCAAATGATGGGTTTGGTG-3′ 
reverse 5′-TCATAAGCCAAACCATTGCCCAGC-3′ 
APH1A 
forward 5′-ATCCGCCAGATGGCCTATGTTTCT-3′ 
reverse 5′-AGCAGGATAATGGCTGCTGTCAGA-3′ 
APH1B 
forward 5′-TTATGTCTTCACCATCGCCACCGA-3′ 
reverser 5′-TTGCCATGAACCAAACAAGGGACG-3′ 
BACE1 
forward 5′-ATGTTGCCACTCTGCCTCATGGTA-3′ 
reverse 5′-TGAGCAGGGAGATGTCATCAGCAA-3′ 
BACE2 
forward 5′-TGAGGACCTTGTCACCATCCCAAA-3′ 
reverse 5′-TGGCCAAAGCAGCATAAGCAAGTC-3′ 
18S 
rRNA 
forward 5′-TTAGAGTGTTCAAAGCAGGCCCGA-3′ 
reverse 5′-TTGGCAAATGCTTTCGCTCTGGTC-3′ 
β-Actin 
forward 5′-ACCAACTGGGACGACATGGAGAAA-3′ 
reverse 5′-TAGCACAGCCTGGATAGCAACGTA-3′ 
GAPDH 
forward 5′-TCGACAGTCAGCCGCATCTTCTTT-3′ 
reverse 5′-ACCAAATCCGTTGACTCCGACCTT-3′ 
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Figure 4.1 Plasma leptin negatively correlates with brain Aβ. 
There was a strong negative correlation between plasma leptin and brain Aβ in young (2–
3 month-old) APP
 KM670/671NL
 × PS1
P264L
 knock-in mice (n= 37 wild type, 49 
heterozygotes, 21 homozygotes; ANOVA, p ≤ 0.0001). Experiment performed by Dr. 
Dana Neidowicz (Niedowicz, Studzinski et al. 2013). 
  
72 
 
 
  
73 
 
Figure 4.2 Leptin treatment inhibits Aβ production in cell culture. 
Leptin reduced the Aβ concentration in conditioned media from APP KM670/671NL -
overexpressing H4 neuroglioma cells after 24 h of treatment (ANOVA, * = p ≤ 0.05), 
concomitant with accumulation of APP C-terminal fragments (CTFα and β: B), indicative 
of reduced γ-secretase activity. Two independent experiments were performed. A is an 
average of the two experiments, while B is a representative immunoblot of the results. 
Experiment performed by Dr. Dana Neidowicz (Niedowicz, Studzinski et al. 2013). 
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Figure 4.3 Leptin treatment reduces mRNA levels of γ-secretase components in cell 
culture. 
mRNA expression of the γ-secretase components PS1, PEN2, nicastrin, and APH1 were 
decreased after leptin treatment in wild-type neuronal tissue culture cells. On the 
contrary, there was an overall increase in the expression of BACE2 (ANOVA, p = 0.014), 
one of the β-secretase enzymes. There was no change in PS2 or BACE1 mRNA 
expression (ANOVA, p > 0.12). The data are an average of 2–3 independent experiments. 
Experiment performed by Dr. Dana Neidowicz (Niedowicz, Studzinski et al. 2013). 
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Figure 4.4 db/AD Characteristics. 
The diabetic LepR
db/db
 mouse was crossed to the APP/PS1 knock-in model of AD to 
create the db/AD line. (A - B) db HOM mice displayed significant weight-gain at an early 
age, and there was no effect of the AD genotype (ANOVA, * = p≤0.01, t-test; Holm-
Bonferroni correction; n= ~14 mice per genotype). In subsequent experiments, we 
focused on the four main genotypes. For simplicity we have named them WT, db, AD, 
and db/AD. (C - D) db and db/AD mice displayed impaired glucose handling by GTT 
(F[2,30] = 38.2, ANOVA, p≤0.0001 for the db genotype overall, n=14 WT; 13 db ; 30 
AD; 18 db/AD, * = p≤0.05, Tukey’s HSD) (E - F) db and db/AD mice were insulin 
resistant (F[15,177] = 4.64, ANOVA, p≤0.0001 for the db genotype overall; n=14 WT; 
13 db ; 30 AD; 18 db/AD; * = p≤0.05, ** = p≤0.01; Tukey’s HSD).  
78 
 
 
  
79 
 
Figure 4.5 db/AD Mice Display Impaired Cognition. 
(A) db/AD mice displayed significant by MWM during the acquisition phase (ANOVA p-
value by day: 0.4, 02, 0.05, 0.001, 0.03; n = 8 WT, 6 AD, 11 db, 8 db/AD). (B) db/AD 
mice displayed deficits during the probe trial, based upon the findings that they spent less 
time in the target quadrant, and less time in proximity to the platform location (ANOVA, 
p≤0.03; * = p≤0.05, ** = p≤0.01. Tukey’s HSD). Experiment performed by Deann 
Hopkins. 
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Figure 4.6 Amyloid Pathology in db/AD Mice. 
(A) Aβ deposition (4G8) in 8 month old mouse neocortex (magnification: 4x). db/AD and 
AD mice displayed amyloid deposition, while db and WT mice did not. (B) Mice with the 
AD genotype displayed increased levels of SDS soluble total Aβ (Ab42.5/4G8) by 
ELISA, and these levels increased with age in these mice (ANOVA, p≤0.0001), but the 
db genotype had no significant effect (ANOVA, * = p≤0.05, compared to WT. [genotype, 
age (6 mo./12 mo.): n = 13/8 WT, 13/8 db, 9/8 AD, 11/7 db/AD). Tissue sectioned and 
stained by NeuroScience Associates. 
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Figure 4.7 Cerebrovascular Pathology in db/AD Mice. 
Vascular casts of mice were created and examined by SEM. (A) WT mice displayed 
normal arterial vasculature; note the clear endothelial cell nuclear imprints and their 
elongated shapes. (B) Aneurysms were observed in the brains of AD and db/AD mice. 
This pathology varied from relatively minor to severe presenting with arterial blebbing 
(C) or complex clusters of saccular aneurysms (D). AD and db/AD mice displayed 
significantly more aneurysms compared to WT and db mice (F[1, 15] = 14.14, p < 0.002 
for the AD genotype overall; N = 4-5). Casting was performed by the lab of Dr. Nada 
Porter.  
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Figure 4.8 Stroke Pathology in db/AD Mice. 
Sequential T2*-MRI was performed on a large set of 12-14 month old mice of the four 
main genotypes. Approximately 70% of db/AD mice displayed evidence of lesions 
(indicated by arrowheads), which are indicative of stroke incidence. Few of these lesions 
were observed in AD mice, though it was uncommon, none were observed in scans from 
WT or db mice (n= 9 WT, 10 db, 11 AD, 26 db/AD). Images were acquired by Dr. David 
Powell. 
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Figure 4.9 db/AD Mice Display Ischemic Stroke Pathology. 
(A-B) T2*-MRI was used to acquire coronal images from an older db/AD mouse. Lesions 
are visible in areas indicated by arrows, which can be indicative of a vascular infarct 
(~300 µm between images). (C - D) The brain from this animal was sectioned 
transversely and stained with Prussian blue and a neutral red counterstain. These sections 
displayed no evidence of hemorrhage, suggesting that this event was an ischemic stroke. 
(E - F) Further analysis of other db/AD mice revealed some Prussian blue staining, 
indicating that some mice do display signs of microhemorrhages, though this was an 
uncommon finding. Staining performed by Dr. Dana Neidowicz. 
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CHAPTER 5: Diabetes, Obesity, and Tau Pathology 
Portions of this chapter are reprinted with permission from: 
Platt TL, Reeves VL, Murphy MP (2013). Transgenic models of Alzheimer's disease: 
better utilization of existing models through viral transgenesis. Biochim Biophys Acta. 
2013 Apr; 1832(9):1437-48 
5.1 – Introduction 
 We demonstrated in Chapter Four that leptin resistance induced obesity and 
diabetes in the AD knock-in mouse model resulted in cognitive impairment and vascular 
pathology, and yet no differences in Aβ generation were detected. While the amyloid 
cascade hypothesis suggests amyloid drives the initial phases of disease, tau pathology 
plays an extensive neurodegenerative role in AD (Ballatore, Lee et al. 2007). As tau 
phosphorylation is closely associated with pathways disrupted by leptin resistance and 
diabetes, in this chapter we explore these mechanisms and their effects on tau 
hyperphosphorylation and tangle formation. 
Multiple studies have demonstrated that tau pathology can be modulated by 
diabetes or obesity. Streptozotocin-induced diabetes results in tau hyperphosphorylation 
in mice (Planel, Tatebayashi et al. 2007). Alterations in tau splice patterns and increases 
in tau phosphorylation have been observed in rodent models of T2DM (Kim, Backus et 
al. 2009, Jung, Park et al. 2011). Additionally, hyperinsulinemic rats display increases in 
tau hyperphosphorylation (Freude, Plum et al. 2005). These changes to tau regulation are 
likely due to dysfunction within the myriad of pathways impacted by obesity and diabetes 
(Virkamaki, Ueki et al. 1999, Schmelzle, Kane et al. 2006, Rains and Jain 2011). Insulin 
signaling transiently modulates tau phosphorylation in primary cortical neurons when 
stimulated with Insulin-like growth factor 1 (Lesort and Johnson 2000). Collectively, 
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these data suggest that diabetes associated metabolic dysfunction influences tau 
phosphorylation, and may promote pathogenesis via increased tau hyperphosphorylation 
(Freude, Plum et al. 2005).  
Insulin signaling is only one of the signaling pathways disrupted in the 
chronically obese or diabetic state. Leptin is a hormone secreted from adipose tissue that 
regulates satiety and energy expenditure via the hypothalamus. The leptin receptor is 
expressed throughout the brain, which suggests it plays additional roles outside 
hypothalamic regulation (Couce, Burguera et al. 1997, Shioda, Funahashi et al. 1998, 
Burguera, Couce et al. 2000). Elevated leptin signaling has also been shown to reduce tau 
phosphorylation (Greco, Sarkar et al. 2008, Marwarha, Dasari et al. 2010). Individuals 
who are obese and diabetic often develop resistance to leptin signaling (Campfield, Smith 
et al. 1995, Halaas, Gajiwala et al. 1995, Considine, Sinha et al. 1996, Ostlund, Yang et 
al. 1996). Leptin signaling classically regulates transcription via Janus Kinase and Signal 
Transducer and Activator of Transcription (JAK-STAT) pathways to modulate energy 
metabolism and satiety (Hakansson and Meister 1998, Elias, Aschkenasi et al. 1999, 
Munzberg, Huo et al. 2003). However, leptin signaling also involves a variety of other 
signaling cascades including the PI3K/AKT, MAPK, and mTOR pathways (Banks, Davis 
et al. 2000, Bjorbaek, Buchholz et al. 2001, Niswender, Morton et al. 2001, Zhao, Huan 
et al. 2002, Rahmouni, Haynes et al. 2003, Cota, Proulx et al. 2006, Cota, Matter et al. 
2008).  Elevated plasma leptin levels have shown to be inversely correlated with 
dementia risk, and leptin treatment has been shown to increase cognition and reduce 
amyloid pathology in transgenic mice (Harvey 2007, Lieb, Beiser et al. 2009, Greco, 
Bryan et al. 2010). In addition, our lab has demonstrated that leptin reduces β-amyloid 
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production, likely as a result of lower γ-secretase expression (Niedowicz, Studzinski et al. 
2013).  
No known mutations are associated with the tau protein in AD. Because of this, 
most transgenic lines utilize mutations from other tauopathies, such as frontotemporal 
dementia (FTD). The JNPL3 transgenic mouse was the first such line to use the FTD 
mutation tau
P301L
, under the PrP promoter, to drive tau pathology (Hutton, Lendon et al. 
1998). NFTs are first detected in these mice at approximately five months, concurrent 
with observations of motor and cognitive dysfunction (Lewis, McGowan et al. 2000). 
The tangles generated in these mice differ from AD tangles, with notable differences in 
tangle morphology, location, and density (Lewis, McGowan et al. 2000). Some of these 
differences can be explained by the fact that the tau
P301L
 mutation generates 4R length tau 
protein, where AD tangles are composed of 3R and 4R isoforms (Nasreddine, Loginov et 
al. 1999).  Another difference is that these animals also exhibit neuronal loss throughout 
the spinal cord (Lewis, McGowan et al. 2000). Spinal cord pathology is also observed in 
Tg2576 mice, which utilizes the same PrP promoter, indicating that the PrP promoter 
induces significant spinal cord overexpression of the transgene. 
 The hTau mouse is a knock-out of endogenous rodent MAPT coupled with the 
addition of a transgene expressing full length wild type human MAPT (Andorfer, Kress et 
al. 2003). This line expresses the full length human MAPT gene alternative splicing 
occurs, resulting in the expression all six isoforms of the human tau protein. These mice 
show signs of tau hyperphosphorylation at approximately six months and NFT formation 
by 15 months (Andorfer, Kress et al. 2003). NFTs in these mice are distributed 
throughout the hippocampus and neocortex, roughly following the progression of tangle 
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pathology seen in AD (Braak and Braak 1991). A decline in memory and cognitive 
function can be observed by approximately 12 months of age, before the onset of 
neurodegeneration (Polydoro, Acker et al. 2009).  
Most mouse models are typically created by microinjecting complementary DNA 
(cDNA), containing a transgene of interest into the pronuclei of a large number of 
zygotes (Cho, Haruyama et al. 2009). Resulting embryos are then implanted into 
pseudopregnant dams for normal gestation. Producing gene targeted mice is a more 
involved process, although knock-out lines for many genes in the mouse are now 
available (https://www.komp.org/). Though now creating a simple modification to the 
mouse genome is relatively routine, generating viable animals can take many attempts 
and consume a significant amount of resources. After the initial genetic modification is 
made, a new mouse line can be crossed into a pre-existing line that already displays one 
or more other aspects of the disease pathology. Hence, given sufficient time and funding, 
one could build increasingly complex models of the disease. 
Despite many concerted attempts, none of our existing mouse models are perfect 
surrogates for AD. This does not mean that these models are without merit. Through the 
use of mouse models, many of the underlying mechanisms that drive AD pathology and 
neurodegeneration have been elucidated. Most, but not all, models overexpress proteins 
involved with the disease (Duff and Suleman 2004, Hall and Roberson 2012). Some 
models have predominantly amyloid pathology, others tau pathology, and a few have 
both. However, for many investigators, the complex interactions between AD and other 
genetic factors are becoming the main focus of their research. This creates a serious 
logistical problem. Our pre-existing mouse models are already complex, and often 
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involve multiple genetic modifications to reasonably mimic AD neuropathology. As a 
simple example, consider a situation with a mouse line harboring mutations in three AD 
associated genes, APP, PS1 and MAPT. If these genes assort independently, and wild 
type littermate controls are needed for an experiment, then a basic husbandry scheme will 
only generate about 3% usable animals. Although there are ways that this can be 
streamlined in practice, three germline modifications represent the practical upper limit as 
to what can be accommodated in a modern laboratory. Because we faced these challenges 
in creating the db/AD line, we were not yet to a point where it would be feasible to create 
a new transgenic line combining a tau transgenic model with the Lepr
db/db
 model. Instead 
we looked to other technologies which can allow in vivo introduction of transgenes.  
Viral gene therapy was once thought to be the pinnacle for the treatment of 
diseases and the future of medicine (Friedmann and Roblin 1972). Unfortunately, the 
safety of such technologies was brought into question after a patient fatality in a clinical 
trial using adenoviral vectors (Wilson 2009). Although the future of therapeutic gene 
delivery is still debatable, the use of viral vectors to alter gene expression in animals has 
expanded significantly. It is through viral transgenesis that existing AD mouse models 
can be better utilized, reducing monetary cost and time investment as well as allowing 
rapid, large scale screens of potentially AD related genes. Adenoviruses have been useful 
tools in some fields due to their high efficiency and ease of production, but offer only 
transient expression and can trigger a significant immune response, reducing their use in 
brain research (Brody and Crystal 1994, Roth and Cristiano 1997, Kibbe, Murdock et al. 
2000, Stephenson 2001).  
93 
 
In recent years, recombinant AAVs (rAAV) have come into their own with new 
technological breakthroughs, correcting many of the previous deficiencies, and 
conferring greater  therapeutic potential (Flotte, Trapnell et al. 2011, Bowles, McPhee et 
al. 2012). AAVs are small non-enveloped parvoviruses which use single-stranded DNA 
as their genetic material (Mori, Wang et al. 2004, Daya and Berns 2008). Upon infection, 
viral single-stranded DNA is taken up into the nucleus, converted to double stranded 
DNA, and is expressed throughout the life of the cell. These viruses are dependent on 
other viruses, such as adenovirus or herpes simplex virus to achieve proper infection 
(Atchison, Casto et al. 1965, Georg-Fries, Biederlack et al. 1984). Wild type AAV has 
the ability to integrate into a specific site of human chromosome-19 (Kotin, Siniscalco et 
al. 1990, Giraud, Winocour et al. 1994); this feature has been removed in modern rAAVs 
(Huser, Gogol-Doring et al. 2010).  
Currently, ten different serotypes of AAVs have been well described (Cearley and 
Wolfe 2006, Zincarelli, Soltys et al. 2008). The primary difference between serotypes lies 
in the capsid amino acid sequence, which alters the tropism of each serotype for different 
cell types (Chiorini, Yang et al. 1997, Rutledge, Halbert et al. 1998). The first broadly 
studied serotype was AAV2, which is considered to be one of the least efficient AAVs in 
the CNS as it transduces far fewer cells than other serotypes (Wang, Wang et al. 2003, 
Burger, Gorbatyuk et al. 2004). Serotypes 1, 4, and 5 have shown much greater levels of 
transduction than AAV2 (Wang, Wang et al. 2003). Interestingly, AAV4 has shown an 
affinity to transduce ependymal cells (Wang, Wang et al. 2003). Overall, analysis of each 
serotype showed that AAV8 has the highest transduction efficiency in the CNS (Harding, 
Dickinson et al. 2006). However, this serotype may be overly efficacious as studies have 
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shown that GFP delivery via AAV8 can produce an overabundance of GFP protein, 
resulting in neurotoxicity (Klein, Dayton et al. 2006). Different serotypes have a varying 
degree of specificity within the CNS in regards to transduction efficiency. It has been 
shown that serotype 9 transduces the hippocampus at higher levels than serotypes 7, 8 
and rh10 (Cearley and Wolfe 2006, Klein, Dayton et al. 2008). Serotype 9 also holds 
greater promise as it has been shown to cross the blood brain barrier in the absence of 
permeabilizing reagents and it also preferentially transduces neurons and astrocytes 
(Duque, Joussemet et al. 2009, Foust, Nurre et al. 2009). Similar to serotype 9, serotype 
sh10 has displayed high transduction efficiencies with a small range of spread from the 
site of injection (Cearley and Wolfe 2006). 
These vectors have several advantages. First, rAAVs are particularly useful in 
neurological studies as transgene expression occurs in dividing and quiescent cells, such 
as neurons (Wu, Phillips et al. 1998). Not only do these rAAVs have the ability to 
transduce non-dividing cells, but also the transgene expression in these cells is long 
lasting with the appropriate promoter (McCown 2005). Second, AAVs pose little 
infective risk to humans (Berns, Pinkerton et al. 1975). It is postulated that 85% of the 
human population is infected by AAVs, yet no associated pathology has been observed 
and does not induce a significant immune response (Muzyczka 1992, Zaiss, Liu et al. 
2002). Finally, the replicative ability of these vectors has been eliminated, which reduces 
the likelihood of unintended infection. After it was discovered that two inverted terminal 
repeats facilitate replication of these viruses, they were excised, resulting in a replication 
deficient rAAV system (Kay, Glorioso et al. 2001). rAAV production relies upon trans 
expression of genes, typically packaged into plasmids, derived from adenovirus and the 
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rep and cap genes from the deleted intronic regions (Samulski, Chang et al. 1989, Xiao, 
Li et al. 1998).  
There are disadvantages to utilizing AAVs in transgenesis. The main limitation of 
AAV systems is that the packaging size is generally limited to 4.7kb (Srivastava, Lusby 
et al. 1983) However, there are some exceptions to this limitation. It has been shown that 
AAV5 vectors may carry up to 8.9kb (Allocca, Doria et al. 2008). This small packaging 
size severely limits the practicality of using AAVs for transgenesis. Another drawback of 
AAVs when compared to lentiviruses is the lack of genomic integration. Though 
episomal expression can be long lasting, gene products will not replicate with the 
genome, resulting in a gradual loss of expression in dividing cells. In non-dividing 
neurons, however, this disadvantage is negligible. 
AAVs have been used extensively in the nervous systems of rodents and non-
human primates with high efficiency and expression. In a study by Jaworski et. al., non-
transgenic mice were intracerebrally transduced with AAV vectors carrying APP.SLA 
mutants, which contain the Swedish, London and Australian mutations (Jaworski, 
Dewachter et al. 2009). By six months plaque deposition was observed in the cortex and 
the hippocampus, yet no degeneration was observed (Jaworski, Dewachter et al. 2009). In 
the same study, AAVs delivering wild-type and mutant P301L transgenes induce 
neurodegeneration of pyramidal neurons of the CA1 and CA2 by 12 weeks and induce 
post-mitotic neurons to activate cell-cycle machinery. Additionally, AAV serotypes 9 and 
10 have been shown to effectively deliver tau mutants and to rapidly induce 
neurodegeneration of dopaminergic neurons of the striatum (Klein, Dayton et al. 2008). 
Gene knock-down has also been achieved within the CNS via delivery of siRNAs. 
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Delivery of mTOR siRNA via AAV5 reduced mTOR levels by 80% within the CNS (Xu, 
Chou et al. 2012). A significant reduction of CDK5 was observed in 3xTgAD mice 
transduced with AAV CDK5-miRNA, which resulted in a five-fold decrease in tau 
phosphorylation (Piedrahita, Hernandez et al. 2010). A mouse model of amyloid 
pathology (TASPM; APP
K670N/M671L 
x PS-1
M146V
) transduced with pathogenic tau 
mutations AAV6 Tau
P301S
 or AAV6 3PO displayed increased tau phosphorylation, tau 
aggregation, amyloid plaque deposition, neuronal loss and cognitive impairment (Dassie, 
Andrews et al. 2013).  
Therefore, instead of crossing one of the existing tau transgenic models with the 
Lepr
db/db
 line we transduced the brains of Lepr
db/db
 pups with AAV tau
P301L
 mutant to 
generate model of tauopathy, leptin resistance, obesity, and T2DM. This method saved a 
significant amount of time and financial investment, something we were not prepared to 
do after the generation of the db/AD line. In this chapter we carried out a series of 
experiments exploring the effects of leptin resistance, obesity, and T2DM on the 
development of tau pathology. Additionally, we outline potential mechanisms which may 
influence the development and/or exacerbation of pathology. 
5.2 – MATERIALS AND METHODS 
5.2.1 – Adeno-Associated Virus (AAV) Generation 
For this study we utilized an AAV1 construct as this serotype is known to produce 
robust expression in the brain and maintain expression for up to nine months (Zincarelli, 
Soltys et al. 2008). The tau
P301
 expression construct containing the chicken β-actin 
promoter and the 3’ enhancer woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE), was a kind gift from Dr. Ronald Klein (Louisiana State University in 
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Shreveport, Shreveport, LA). The tau
P301L
 mutation was discovered as familial mutation 
which promotes the development of pathology and induces neurodegeneration and 
dementia in patients with frontotemporal dementia and parkinsonism linked to 
chromosome-17 (FTDP-17), and is commonly used in studying tauopathies (Poorkaj, 
Bird et al. 1998, Spillantini and Goedert 2000, Morris, Khan et al. 2001, Lin, Lewis et al. 
2003). The tau
P301L
 plasmid (pcDNA3), adeno-helper plasmid (pZac2.1), and rep/cap 
(AAV1) plasmids (pZac2.1) were co-transfected into HEK293A cells (ATCC; Manassas, 
VA) (Klein, Lin et al. 2004, Klein, Lin et al. 2004). After 72 hours, the cells were 
harvested and the resulting virus purified by iodixanol gradient, and reconstituted in PBS. 
The AAV vector was then titered for copies of vector genomes with WPRE inclusion by 
quantitative real-time PCR using WPRE-specific primers (Forward: 
GGCTGTTGGGCACTGACAAT, Reverse: CCGAAGGGACGTAGCAGAAG) and RT² 
SYBR Green/ROX qPCR Master Mix (#PA-012-12 SABiosciences; Frederick, MA). The 
AAV copy numbers were between 1 x 10
12
 and 1x10
13
 genomes/mL. These vectors were 
created both in Murphy lab and by the UK Viral Core following the same protocol. A 
control non-expressing AAV1 (CAG.Flex.eGFP.WPRE.bGH) was purchased from the 
University of Pennsylvania Vector Core (AAV-1-ALL854). 
5.2.2 – Viral Transduction in vivo 
Viral transduction in each mouse brain was conducted as previously described 
(Levites, Jansen et al. 2006). Briefly, newborn mice, postnatal day 0-2 (P0-P2), were 
gently placed in an aluminum foil envelope and cryoanesthetized on wet ice for 
approximately 5 minutes. AAVs (2 µL/ injection) were injected bilaterally into the 
intracerebroventricular space using a 5 µL syringe (Hamilton; Reno, NV) with a 26 
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gauge needle. Immediately after injection, the pups were warmed under a heat lamp until 
fully recovered before returning them to their home cage. The pups were monitored for 
three days following injection, then weekly for the remainder of the study. A small 
number of mice were left uninjected to use as controls (62 AAV1 tau
P301L 
injected, 28 
control AAV1 injected, and 58 uninjected controls).  
5.2.3 – Glucose Tolerance Test (GTT) 
GTTs were performed two weeks before the end of the study. Mice were fasted 
for 6 hours and fasting blood glucose was taken via tail prick using a hand held 
glucometer (Breeze2, Bayer HealthCare, LLC; Tarrytown, NY). Immediately after the 
baseline glucose measure was taken, the mice were administered an intraperitoneal 
injection of glucose (Hospira; Lake Forest, IL) at a dose of 2g/kg body weight. Blood 
glucose levels were then measured at 15, 30, 60 and 120 minutes after the injection. Any 
reading of ‘HI’ (above the detectable range) was recorded as 700 mg/dL for data analysis. 
5.2.4 – Behavioral Testing 
One week before the end of the study, mice were tested in the Morris water maze 
(MWM) to gauge cognitive function. Mice were trained over five days to locate a 
submerged platform (11 cm) using external cues. The platform was in the northeast 
quadrant of a 134.5 cm diameter pool filled with opaque water (25ºC) containing 
nontoxic white tempura paint. Mice were given 60 seconds to find the platform, and if 
they did not find it within this time period, they were placed on the platform for 15 
seconds to acquaint them with its location. Mice were trained over four 60-second trials 
each day (starting from a different quadrant on each trial), with a minimum five-minute 
interval between trials. At the end of training on the fifth day the platform was removed 
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and a probe trial was performed. Additionally, after the probe trial a single visual acuity 
test was performed during which the platform was moved from its training location to the 
opposite side of the pool and cued with a small white flag. All trials were recorded using 
a video camera and analyzed with EthoVision XT software (Noldus Information 
Technology; Leesburg, VA) to measure swim distance, escape latency, and velocity. 
5.2.5 – Cell Culture 
HEK293 cells stably expressing the tau
P301L
 mutation (a kind gift from Dr. Chad 
Dickey, University of South Florida) were grown in DMEM (Invitrogen) with 10% fetal 
bovine serum (HyClone; Logan, UT), 1% penicillin-streptomycin (Cellgro; Manassas, 
VA) and 120 ng/mL G418 (HyClone) for selective pressure. Cells were treated with 
various concentrations (0, 10, 50, and 100 ng/mL) of recombinant human leptin (Sigma-
Aldrich; St. Louis, MO) for 48 hours and lysed in RIPA buffer (1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50mM Tris, and 150 mM sodium 
chloride, pH = 8.0) supplemented with protease inhibitor cocktail (Amresco; Solon, OH) 
and phosphatase inhibitor (EMD Millipore; Billerica, MA). 
5.2.6 – Western Blotting and ELISAs 
Frozen brain tissue was homogenized with an AHS200 PowerMax polytron 
(VWR; Radnor, PA) in Tris-buffered saline (50mM Tris, 274mM NaCl, and 5mM KCl, 
pH = 7.4) with protease (Amresco) and phosphatase inhibitors (EMD Millipore) at 1mL 
per 100 mg tissue. The homogenate was centrifuged at 13,000 x g for 15 minutes at 4°C 
and the supernatant separated and stored at -80ºC. The protein concentrations of the 
supernatants were determined by bicinchoninic acid assay (Pierce; Rockford, IL). 
Extracts (25 µg) were separated by SDS-PAGE on 4-12% Bis-Tris Criterion gels in 
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MOPS running buffer (Bio-Rad; Hercules, CA) and transferred to a 0.2 µm nitrocellulose 
membrane (Bio-Rad). Following transfer, the membranes were blocked overnight in PBS 
with 1% bovine serum albumin and 2% BlockAce (AbD Serotec, Raleigh, NC). Blots 
were then probed with AT8 (Greco, Bryan et al. 2010, Koike, Green et al. 2010, 
Martinez-Coria, Green et al. 2010, van Eersel, Ke et al. 2010) for pSer202/pThr205 tau 
(#MN1020, Pierce; 1:500), AT180 (Koike, Green et al. 2010, Martinez-Coria, Green et 
al. 2010) for pThr231 tau (#MN1040, Pierce, 1:100), PHF-1 (Martinez-Coria, Green et al. 
2010) for pSer396/pS404 (courtesy of Dr. Peter Davies, Albert Einstein College of 
Medicine, Bronx, NY 1:1000), HT7 (Koike, Green et al. 2010, Martinez-Coria, Green et 
al. 2010, van Eersel, Ke et al. 2010) for total tau (#MN1000, Pierce, 1:1000), and anti-
GAPDH (ab9385, Abcam; Cambridge, MA, 1:5000) antibodies then probed with HRP-
conjugated rabbit anti-mouse secondary antibody (Rockland Immunochemicals; 
Gilbertsville, PA, 1:10,000). Membranes were then incubated with SuperSignal West 
Dura chemiluminescent substrate (Pierce), and then exposed to film. Films were scanned, 
and densitometric analysis was performed using Image J software (NIH; 
www.imagej.net). Total tau (KHB0041, LifeTechnologies), pSer199 tau (KHB7041, 
LifeTechnologies), and pThr181 tau (#80062, Fujirebio; Malvern, PA) were measured by 
sandwich ELISA using commercially available kits according to manufacturer’s 
instructions. Absorbance was measured at 450 nm using a multiwell plate reader 
(BioTek, Winooski, VT). 
5.2.7 – Immunohistochemistry 
Formalin-fixed hemibrains were serially cryoprotected in sucrose (at 
concentrations of 10%, 20%, and 30% sucrose for 24 hours each). Brains were sectioned 
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at 25 µm on a freezing sliding microtome and stored in PBS with 0.05% NaN3. 
Immunohistochemistry was performed using PHF-1 (courtesy of Dr. Peter Davies, 1:100) 
to stain for neurofibrillary tangles, and a mouse on mouse (M.O.M) peroxidase kit 
(Vector Laboratories; Burlingame, CA) with 3,3’diaminobenzidine (DAB; Vector 
Laboratories) for development. Fluorescent double-labeling was also performed for PHF-
1 to stain for neurofibrillary tangles with Alexa Fluor® 568 secondary antibody 
(#A10037, Life Technologies, 1:200), and astrocytes were labeled with Rabbit anti-glial 
fibrillary acidic protein (GFAP) antibody (#PA1-10019, Pierce, 1:1000) and Alexa 
Fluor® 488 secondary antibody (#A11070, Life Technologies,1:200). Slides were cover 
slipped with VECTASHIELD® Mounting Media with DAPI (#H-1500, Vector 
Laboratories). Images were taken using an Olympus BX51 microscope (Olympus; 
Melville, NY) and an Olympus Q-Color5 digital camera (Olympus). Images were 
processed using Image J software (NIH) to perform densitometric analysis. 
5.3 – RESULTS  
5.3.1 – Tau Phosphorylation in Leprdb/db Mice 
To determine if tau phosphorylation was altered in the db/AD mice we performed 
dotblot analysis. We observed that mice homozygous for the db mutation displayed 
significantly increased levels of tau phosphorylation (p = 0.03, n = 22 Lepr
+/+
, 50 
Lepr
+/db
, 24 Lepr
db/db
) (Figure 5.1). Though this increase in tau phosphorylation is 
interesting, rodent tau does not naturally form (PHFs) or NFTs. It is, thus, not possible to 
study the effect of diabetes on tangle pathology in this model.  We, therefore, turned to 
AAV technology, which facilitates rapid production of a large number of dual transgenic 
animals (Platt, Reeves et al. 2013). 
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5.3.2 – Leptin Regulates Tau Phosphorylation in vitro  
The key characteristic which drives pathology in Lepr
db/db
 mice is the abolishment 
of leptin signaling. If the lack of leptin signaling promotes the development of pathology, 
then it stands to reason that leptin itself may act as an inhibitor towards the development 
of tau pathology. Previous studies have shown leptin treatments reduce tau 
phosphorylation in vitro (Greco, Sarkar et al. 2008, Marwarha, Dasari et al. 2010). To 
determine if the increase in tau phosphorylation in Lepr
db/db
 mice is directly related the 
leptin signaling axis, we tested how increased leptin signaling would affect tau 
phosphorylation in vitro.  Tau
P301L
 expressing HEK293 cells were treated within a 0 to 
100 ng/mL range of recombinant human leptin. Leptin treatment induced a dose-
dependent reduction in tau phosphorylation at the pSer202/Thr205 (AT8) and pThr231 
(AT180) epitopes as shown via Western blot (Figure 5.2A-B). Additionally, we 
incubated SH-SY5Y cells with varying concentrations of oligomeric tau, which we 
showed in chapter 3 is cytotoxic to cells, and treated half the cells with 100 ng/mL leptin 
to determine if leptin’s reported neuroprotective effects may reduce oligomeric tau 
cytotoxicity. Leptin treatment had no effect on reducing the cytotoxicity of oligomeric 
tau (Figure 5.2C; p = 0.191). These results indicate that leptin inhibits tau 
phosphorylation, and suggest that this may be the mechanism for the increase tau 
phosphorylation observed in the Lepr
db/db
 mice. 
5.3.3 – Characteristics of the Leprdb/db Mouse Model 
In order to better explore the impact diabetes and obesity may have on the 
development of tangle pathology, independent of amyloid pathology, we transduced the 
brains of Lepr
db/db
 mice with a tau mutant, tau
P301L
. Though the tauopathy observed in 
AD does not occur due to a genetic defect, tau mutations are found in other tauopathies. 
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This mutation is commonly used to produce tangle pathology in rodent models (Lewis, 
McGowan et al. 2000, Gotz, Chen et al. 2001). The tau
P301L
 mutation was discovered as 
familial mutation which promotes the development of pathology and induces 
neurodegeneration and dementia in patients with frontotemporal dementia and 
parkinsonism linked to chromosome-17 (FTDP-17) (Hutton, Lendon et al. 1998, Poorkaj, 
Bird et al. 1998, Spillantini, Murrell et al. 1998, Morris, Khan et al. 2001). This mutation 
is commonly used and is known to produce tangle pathology in rodent models (Lewis, 
McGowan et al. 2000, Gotz, Chen et al. 2001).  
Characterization of these mice revealed that mice homozygous for the db 
mutation (Lepr
db/db
) weighed significantly more than wild-type (Lepr
+/+
) or heterozygous 
(Lepr
+/db
) littermates (p = 0.001, n = 18 Lepr
+/+
, 42 Lepr
+/db
, 30 Lepr
db/db 
), and displayed 
accelerated weight gain from weaning (Figure 5.3A-B). No weight differences were 
observed between genders until five and six months where males of all genotypes 
weighed significantly more than their female counterparts (data not shown; 5 months: p < 
0.001, 6 months: p < 0.001; n = 7F/11M, Lepr
+/+
, 18F/24M Lepr
+/db
, 14F/16M Lepr
db/db
). 
Additionally, GTT analysis showed that mice homozygous for the db mutation displayed 
impaired glucose handling compared to wild-type and heterozygous littermates (Figure 
5.3C-D: p < 0.001, n = 18 Lepr
+/+
, 45 Lepr
+/db
, 25 Lepr
db/db
). Males displayed an even 
greater impairment in glucose handling compared to females (data not shown; p < 0.01, n 
= 8F/10M, Lepr
+/+
, 18F/27M Lepr
+/db
, 14F/13M Lepr
db/db
). AAV injection with either the 
control or tau
P301L
 constructs had no effect on glucose handling (Figure 5.3E-F: p = 
0.001, n = 26 uninjected, 27 control AAV1, 35 AAV1 tau
P301L
). These data indicate that 
mice homozygous for the db mutation have metabolic dysfunction, consistent with 
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previous reports (Chua, Chung et al. 1996, Koch, Augustine et al. 2010), and that 
expression of mutant tau had no impact on this phenotype 
5.3.4 – Mice Transduced with TauP301L Express Higher Levels of the Tau Protein  
At six months of age, mice were euthanized and their tissues harvested. Mice 
transduced with AAV1 tau
P301L
 expressed significantly higher levels of tau than 
uninjected animals (Figure 5.4A-B: p < 0.005, n = 13 uninjected [5 Lepr
+/+
, 3 Lepr
+/db
, 5 
Lepr
db/db
] / 11 tau
P301L 
[5 Lepr
+/+
, 3 Lepr
+/db
, 3 Lepr
db/db
]). It is also interesting to note that 
some AAV1 tau
P301L
 samples display large protein smears on Western blot (Figure 5.4A) 
indicating that large amounts of tau aggregates are present in the homogenate, indicative 
of tangle pathology. Total tau levels were not significantly different between genotypes 
(Figure 5.4C: p = 0.172, n = 10 Lepr
+/+
, 23 Lepr
+/db
, 10 Lepr
db/db
) though there was a 
slight trend towards a reduction of total tau in homozygous db mice (p = 0.172). The 
amount of tau phosphorylation was significantly higher in homozygous db mice 
compared to the other genotypes (Figure 5.4D-E: pSer 199 tau p < 0.05, pThr 181 tau p 
< 0.05, n = 10 Lepr
+/+
, 23 Lepr
+/db
, 10 Lepr
db/db
). As only the AAV tau
P301L
 injected mice 
display increased tau expression uninjected and non-expressing AAV injected mice will 
collectively be referred to as the ‘control’ group henceforth. These data support the 
hypothesis that leptin resistance, obesity, and diabetes increase tau phosphorylation in 
vivo.  
 To determine if NFT pathology was exacerbated by diabetes, we examined brain 
sections from injected mice by IHC (Figure 5.5). AAV1 tau
P301L
-injected mice 
developed tangle pathology in the neocortex and hippocampus (Figure 5.5A), typically 
present in large pyramidal neurons (Figure 5.5B). Direct comparison of AAV1 tau
P301L
-
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injected mice (Figure 5.5C & E) to control mice (Figure 5.5D & F), illustrated the 
dramatic extent of tangle pathology which developed in mice expressing the tau
P301L
 
mutation. To determine the interaction between genotype and tangle burden, five sections 
from 15 mice, five of each genotype, were labeled with PHF-1 (Figure 5.6A-C). 
Consistent with the observed increase in tau phosphorylation, db homozygotes displayed 
more extensive tangle pathology than their wild-type or heterozygous littermates (Figure 
5.6D). Interestingly, other tangle-like structures, which resembled astrocytes, were also 
observed throughout the brain (Figure 5.7A). Fluorescent co-labeling with PHF1 and 
anti-GFAP antibodies indicated that tangles were indeed present in a small subset of 
astrocytes (Figure 5.7B). 
5.3.5 – Cognitive Function 
Finally, in order to determine if the observed tangle pathology induced cognitive 
deficits we performed a basic Morris Water Maze test. Previous studies using AAV1 
vectors to transduce the tau
P301L
 mutation indicate extensive tangle pathology develops by 
6 months of age, therefore one week before the 6 month endpoint mice were tested for 
cognitive deficits (Klein, Lin et al. 2004). For all training days, swim distance was not 
significantly different between the three genotypes (Figure 5.8A: p = 0.959, n = 18 
Lepr
+/+
, 45 Lepr
+/db
, 26 Lepr
db/db
). Escape latency for db homozygous animals was 
significantly higher, a finding likely explained by the slight reduction in observed swim 
speed (data not shown, p < 0.001). There was no difference in swim distance between 
AAV control and AAV1 tau
P301L
 injected animals (Figure 5.8B: p = 0.862, n = 54 
control, 35 AAV1 tau
P301L
). After the fifth day of acquisition trials, a probe trial was 
performed to test spatial memory. Interestingly, db heterozygotes spent significantly 
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more time in the target quadrant than the other genotypes (p = 0.044 compared to 
Lepr
+/+
), whereas AAV1 tau
P301L
 injection had no effect (p = 0.992; Figure 5.8C: 
genotype:  n = 18 Lepr
+/+
, 45 Lepr
+/db
, 26 Lepr
db/db
; treatment: p = 0.473, n = 35 AAV1 
tau
P301L
, 54 control).  
Diabetic retinopathy is a common secondary complication of diabetes and has 
previously been reported in Lepr
db/db
 mice as early as 22 weeks of age (Midena, Segato et 
al. 1989, Clements, Robison et al. 1998, Cheung, Fung et al. 2005). Therefore, in order to 
determine if there was a visual impairment in db homozygotes that could potentially 
affect MWM performance, we performed a visual acuity test. In this test all mice 
displayed similar swim distances to the platform (Figure 5.8D: genotype: p = 0.118, n = 
18 Lepr
+/+
, 45 Lepr
+/db
, 26 Lepr
db/db
; treatment: p = 0.59, n = 35 AAV1 tau
P301L
, 54 
control) regardless of genotype or treatment, indicating that there were no significant 
visual deficits.  
5.3.6 – Signaling Mechanisms 
 To explore some of the mechanisms which may drive tau pathology we probed 
various regulatory phosphor-epitopes of GSK3β, AMPK, MAPK, and AKT (Figure 5.9). 
Phosphorylation of GSK3β at serine 9 inhibits GSK3β activity (Cai, Wang et al. 2007). 
Lepr
db/db
 mice display decreased phosphorylation of at this epitope (p ≤ 0.05), suggesting 
an increase in GSK3β activity and potentially tau phosphorylation (Figure 5.9A). 
Additionally, phosphorylation of AMPK at threonine 172 is increased in these mice, 
indicated AMPK activity is elevated, which can result in increased tau phosphorylation (p 
≤ 0.05; Figure 5.9B) (Hardie and Carling 1997). A reduction in phosphorylation at 
threonine 202 of MAPK is observed in Lepr
db/db
 mice (Figure 5.9C), but is not quite 
107 
 
significant (p = 0.086) (Chuenkova and Pereira 2001). Though total AKT levels are 
significantly elevated in Lepr
db/db
 mice (data not shown; p ≤ 0.05) activation of AKT is 
not elevated by phosphorylation of serine 473 (p = 0.752; Figure 5.9D). Representations 
of the western blots can be observed in Figure 5.9E. 
5.4 – CONCLUSIONS 
The influence of leptin resistance, obesity, and diabetes on tau pathology in 
neurodegeneration remains unclear, largely due to the complex metabolic state of these 
conditions. Leptin has been shown to be protective against stroke, excitotoxicity, and 
neuropathy (Dicou, Attoub et al. 2001, Zhang, Wang et al. 2007, Guo, Jiang et al. 2008, 
Lieb, Beiser et al. 2009, Perez-Gonzalez, Antequera et al. 2011). Reports have also 
indicated that leptin may improve cognition and modulate hippocampal synaptic 
plasticity (Shanley, Irving et al. 2001, Wayner, Armstrong et al. 2004, Farr, Banks et al. 
2006, Oomura, Hori et al. 2006, Paz-Filho, Babikian et al. 2008). Similarly, several 
studies have demonstrated that deficient leptin signaling, as a result of mutation or 
resistance, can impair cognition (Li, Aou et al. 2002, Harvey and Ashford 2003, 
Winocur, Greenwood et al. 2005). In this study, we demonstrate that leptin induced 
obesity and diabetes modulate tau phosphorylation pathways, resulting in increased tau 
phosphorylation, and that this in turn leads to accelerated development of tangle 
pathology.  
 Leptin functions through JAK/STAT signaling pathways, activating downstream 
regulatory kinases such as MAPK, AKT, and mTOR, all of which play key roles in many 
global pathways, but also in regulating tau’s phosphorylation state (Augustinack, 
Schneider et al. 2002, Cavallini, Brewerton et al. 2013). It is also interesting to note that 
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these three regulatory pathways inhibit glycogen synthase kinase-3β (GSK3β), thought to 
be the primary kinase involved in pathologic tau hyperphosphorylation (Frame and 
Cohen 2001, Lee 2011). Leptin-mediated inhibition of GSK3β activity has been reported, 
and it is logical to deduce that GSK3β activity would be increased in the absence of leptin 
signaling, leading to increased tau phosphorylation (Valerio, Ghisi et al. 2006). 
What is perhaps most interesting, is that AMPK activity was found to be elevated 
in the brains of Lepr
db/db
 mice. This was an unexpected finding as AMPK activity is 
typically found to be low in the muscles of T2DM patients (Viollet, Lantier et al. 2009). 
AMPK can be activated by increased adenosine monophosphate (AMP) concentrations, a 
hallmark of low cellular metabolism. In addition to elevated levels of AMP, a secondary 
phosphorylation of AMPK’s by AMPK kinases (AMPKKs) like liver kinase B1, 
transforming growth factor-β-activated kinase 1, and Ca2+-calmodulin-dependent kinase 
β can activate AMPK activity (Wang, Jiang et al. 2010). It is possible that these findings 
are unique to this particular stage of insulin resistance at this age in the Lepr
db/db
 mice. 
This could suggest that AMP levels suddenly fall off around 6 months, while AMPK 
phosphorylation is high, resulting in the increased activity we observed. The increased 
AMPK activity found in the brains of these mice is counter-intuitive and warrants further 
investigation in regards to its increased activity and ability to hyperphosphorylate tau. 
 Despite increases in tangle pathology, these mice displayed no impairments in 
learning or memory, as tested by the MWM. The absence of any observed deficits in 
learning or memory were not entirely surprising. Other traditional transgenic models, 
which utilize the tau
P301L
 mutation, display cognitive deficits at around 16 months of age 
(Harris, Koyama et al. 2012). Our model has more diffuse expression than the tau models 
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used in those studies and may display significant cognitive deficits at ages beyond 6 
months. It is quite possible that neurodegeneration is minimal at this age though 
pathology is developing in the brains of these mice. One barrier we encountered when 
using the Lepr
db/db
 model previously is that these mice have a substantially decreased 
lifespan (~10-12 months) and can develop quite severe complications associated with 
obesity and metabolic dysfunction. While the Lepr
db/db
 line has proven to be an excellent 
model of obesity and diabetes, any future studies with these mice will need to delicately 
balance possible age requirements needed to read a neurodegenerative state with the 
innate morbidity and mortality of these mice.     
 In addition to future studies in aged mice, altering the AAV vector itself could 
provide some benefit. This study utilized an AAV serotype 1 vector. While injected mice 
displayed extensive tangle pathology, utilizing another serotype could provide slightly 
better results. Other AAV serotypes, such as 8 and 9 have been shown to have the highest 
transduction efficiencies within the CNS, are able to provide robust expression within the 
hippocampus, and cross the blood-brain barrier more easily than other serotypes (Cearley 
and Wolfe 2006, Harding, Dickinson et al. 2006, Klein, Dayton et al. 2008, Duque, 
Joussemet et al. 2009). Using a different AAV serotype may allow for higher 
transduction efficiencies and more advanced pathology, though further experiments 
would be required to determine if they would yield better results than our current AAV 
serotype. Though the CBA promoter of the virus should transduce all cell types, it is 
possible other promoters could enhance transgene expression. Studies indicate that the 
human synapsin promoter, which selectively transduces neurons, can induce more potent 
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transgene expression than other promoters, including the CBA promoter (Shevtsova, 
Malik et al. 2005). 
In conclusion, we have demonstrated that a model of dysfunctional leptin 
signaling, obesity, and uncontrolled T2DM has increased tau phosphorylation and tangle 
pathology. This study establishes a connection between metabolic dysfunction and 
tauopathies. This study also paves way for the development of potential therapeutic 
interventions, which could involve modulation of kinase activity with compounds such as 
lithium, rapamycin, or T2DM therapeutics. These studies would help determine which 
pathways directly impact pathology in this model. Additional studies into the activity 
states of important tau kinases also warrant investigation in this model. 
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Figure 5.1 Tau Phosphorylation is Increased in db Homozygous Mice. 
(A) Homozygous db mice showed an increase in tau phosphorylation (shown: phospo-tau 
[AT8]; total tau [HT7] and β-actin [AC15]; ANOVA, F[2,97]=2.917, p < 0.02, n = 22 
Lepr
+/+
, 50 Lepr
+/db
, 24 Lepr
db/db
). The increase was also significant when not 
standardized to total tau (p < 0.03, not shown). No difference between sexes was 
observed (p = 0.182, n = 45 female, 51 male). (B) The AD genotype did not affect tau 
phosphorylation (p = 0.647).  
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Figure 5.2 Leptin Treatment Reduces Tau Phosphorylation but not Oligomeric Tau 
Cytotoxicity. 
(A-B HEK293 cells stably transfected with tau
P301L
 display a dose dependent reduction in 
tau phosphorylation when treated with recombinant human leptin (ANOVA, 
F[3,8]=0.016; AT180: p ≤ 0.05; AT8 p = 0.108). (C) Leptin treatment (100 ng/mL) did 
not reduce oligomeric tau cytotoxicity (ANOVA, F[5,42]=11.208; p = 0.191). 
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Figure 5.3 Phenotypic Characteristics of Lepr
db/db
 Mice. 
Mice homozygous for the db genotype were obese, whereas wild-type and heterozygous 
mice maintained a normal body weight (A-B) (4 month old littermates, right: Lepr
+/db
; 
middle: Lepr
db/db
 ; left: Lepr
+/+
. ANOVA, p < 0.001, n =18 Lepr
+/+
, 45 Lepr
+/db
 25 
Lepr
db/db
). At five and six months males of all genotypes weighed more than female 
counterparts (data not shown; 5 months: p < 0.001, 6 months: p < 0.001; n = 7F/11M, 
Lepr
+/+
, 18F/24M Lepr
+/db
, 14F/16M Lepr
db/db
). Mice homozygous for the db genotype 
had impaired glucose handling as determined by glucose tolerance test (C–D) (Repeated 
measures ANOVA, F[2,85]=11.046; * = p < 0.001, n = 18 Lepr
+/+
, 45 Lepr
+/db
, 25 
Lepr
db/db
). Males displayed a greater impairment in glucose tolerance (data not shown; p 
< 0.01, n = 8F/10M, Lepr
+/+
, 18F/27M Lepr
+/db
, 14F/13M Lepr
db/db
). AAV injection had 
no effect on glucose handling (E–F) (ANOVA, F[2,85]=0.074; p < 0.879, n = 26 
uninjected, 27 control AAV1 injected, 35 tau
P301L
 injected).  
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Figure 5.4 AAV1 Tau
P301L
 Expression in db Mice. (A-B) 
A cohort of mice were injected with AAV1 tau
P301L
 at P0-P2 and expression levels of 
total tau (HT7) were evaluated by Western blot after six months (ANOVA, 
F[2,40]=2.641, p < 0.05; n = 13 uninjected [5 Lepr
+/+
, 3 Lepr
+/db
, 5 Lepr
db/db
] / 11 tau
P301L 
[5 Lepr
+/+
, 3 Lepr
+/db
, 3 Lepr
db/db
]). (C) Lepr
db/db
 mice did not displayed significantly 
different levels of total tau, as measured by sandwich ELISA, though they did appear to 
have slightly less total tau (p = 0.172, n = 10 Lepr
+/+
, 23 Lepr
+/db
, 10 Lepr
db/db
) (D-E) 
Phospho-tau Ser199 and Thr181 levels were also measured by ELISA. Both epitopes 
showed a significant increase in the percentage of tau phosphorylation, standardized to 
total tau, in db homozygotes compared to other genotypes (p181 Tau: ANOVA, 
F[2,40]=3.199, p199 Tau: ANOVA, F[2,40]=3.0.92, * = p < 0.05; n = 10 Lepr
+/+
, 23 
Lepr
+/db
, 10 Lepr
db/db
). 
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Figure 5.5 Tangle expression in AAV1 Tau
P301L
 injected mice. 
(A) AAV1 tau
P301L
 injected brain section of a db homozygous mouse stained with PHF-1 
primary antibody. Extensive tangle pathology developed in the hippocampus of these 
mice at 6 months of age. (B) Large neurofibrillary tangles could also be observed in the 
cortex. (C – F) TauP301L injected mice displayed extensive PHF1 immunoreactivity 
compared to uninjected controls (Top: PHF-1, Bottom: Nuclei stained with DAPI for 
anatomical reference). Note that no PHF1 immunoreactivity is observed in mice not 
injected with AAV1 tau
P301L
. 
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Figure 5.6 Lepr
db/db
 Mice Display Tangle Pathology Within the Hippocampus. 
(A-C) AAV1 tau
P301L
 injected hemibrains were sectioned and stained for PHF-1 to 
determine the extent of tangle pathology in the hippocampus (A: Lepr
+/+
 B: Lepr
+/db
, C: 
Lepr
db/db
). (D) Densitometric analysis of these sections indicated that db homozygotes 
displayed increased PHF1 immunoreactivity than the wild-types or heterozygotes ( 
ANOVA, F[2,12]=4.604, p < 0.05, n = 5 Lepr
+/+
, 5 Lepr
+/db
, 5 Lepr
db/db
). 
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Figure 5.7 Astrocytic Tangles are Present in AAV1 Tau
P301L
 Mice. 
(A) In addition to tangles in pyramidal neurons, tangles were present in astrocytes 
(arrows). (B) Co-labeling with PHF1 and anti-GFAP antibodies revealed co-localization 
of NFTs within a subset of astrocytes (arrows). 
  
125 
126 
 
Figure 5.8 Mice Have No Deficits in Memory or Learning Based on Morris Water 
Maze Analysis. 
(A - B) There were no significant differences by genotype or treatment (Repeated 
Measures ANOVA, F[2,2]=.042, genotype: p = 0.837, n = 18 Lepr
+/+
, 45 Lepr
+/db
, 26 
Lepr
db/db
, treatment: Repeated Measures ANOVA, F[2,1]=.031, p = 0.633, n = 54 control, 
35 AAV1 tau
P301L
 injected). (C) On the last day of training after the final trial, the 
platform was removed and mice underwent a probe trial. Heterozygotes performed 
significantly better at this trial than their counterparts, and treatment had no effect 
(genotype: ANOVA, F[2,86]=6.285, p < 0.05, n = 18 Lepr
+/+
, 45 Lepr
+/db
, 26 Lepr
db/db
; 
treatment: ANOVA, F[2,87]=0.923, p = 0.473, n = 54 control, 35 AAV1 tau
P301L
 
injected) (D) After the probe trial the platform was placed in the tank within the 
southwest quadrant and flagged to make the platform visible. Neither genotype nor 
treatment had any significant effect (genotype: ANOVA, F[2,86]=2.858, p = 0.118, n = 
18 Lepr
+/+
, 45 Lepr
+/db
, 26 Lepr
db/db
, treatment: ANOVA, F[2,87]=2.988, p = 0.59, n = 54 
control, 35 AAV1 tau
P301L
 injected).  
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Figure 5.9 GSK3β and AMPK are activated in Leprdb/db mice. 
Lepr
db/db
 mice display decreased phosphorylation at the serine 9 epitope of GSK3β is 
reduced (ANOVA, F[2,12]=3.562, p ≤ 0.05; A). Increased phosphorylation at threonine 
172 of AMPK is also increased in these mice (ANOVA, F[2,12]=6.942, p ≤ 0.05; B). A 
reduction in phosphorylation at threonine 202 of MAPK is observed in Lepr
db/db
 mice 
(C), but is not quite significant (ANOVA, F[2,12]=3.581, p = 0.086). Phosphorylation at 
serine 473 of AKT is not different between any of the genotypes (ANOVA, 
F[2,12]=4.018, p = 0.752; D). GAPDH expression was not significant between any 
genotypes and was used as a loading control (ANOVA, F[2,12]=2.241, p = 0.58; E). 
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
6.1 – SUMMARY 
In chapter three, we evaluated mechanisms by which tau pathology can develop 
and how pathology may lead to neurodegeneration. First we evaluated the effects of 
knocking-down GSK3β expression using anti-sense oligonucleotide technology in 
SAMP8 mice. GSK3β is believed to be a major kinase involved in tau pathogenesis. 
Inhibiting the expression of this kinase is thought to be a key therapeutic intervention for 
treating tauopathies. Knock-down of GSK3β revealed a significant reduction in 
phosphorylated tau (pThr231), as was expected (Figure 3.1).   
Tau pathology is not only initiated by aberrant phosphorylation events. 
Alternative splicing of tau can result in unequal inclusion of microtubule binding 
domains (3R:4R ratio) which can result in pathogenesis. We evaluated this effect in 
myotonic dystrophy cases. Myotonic dystrophy is a splicing disease in which expansions 
in either DMPK (Type I DM) or ZNF9 (Type II DM) sequester splicing machinery, 
leaving other transcripts without proper processing by the spliceosome. Individuals with 
DM develop muscle wasting, but also develop a series of other pathologies including 
tauopathy. Western blot analysis of DM cases revealed that expression of tau isoforms 
were altered, with DM case samples expressing lower molecular weight tau isoforms not 
seen in control cases. Additionally, expression of other proteins associated with 
neurodegenerative disease, such as BACE1 and BIN1, are found to be expressed at 
higher levels in DM cases.  
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Next, we tested which tau structures (monomers, fibrils, and oligomers) were 
most cytotoxic. Initial studies revealed tau oligomers were cytotoxic to SH-SY5Y cells, 
whereas monomers and fibrils were not (Figure 3.3A). To explore the toxic 
characteristics of oligomeric tau both primary rat hippocampal neurons and SH-SY5Ys 
were treated with varying concentrations of tau oligomers (Figure 3.3B-C). Cytotoxicity 
of oligomers was significant at concentrations of 50 nM and higher. These findings were 
important to verify which tau species is most cytotoxic to both immortalized cell lines 
and primary neuronal culture.  
Finally, we wanted to determine if T2DM may influence the development of 
pathology in AD patients. To do so, we compared pathologic data from normal, diabetic, 
AD, and diabetic AD patients. Interestingly, diabetic AD patients displayed significant 
reductions in tangle counts in all brain regions except the occipital lobe, which is likely 
due to the fact that the occipital lobe is relatively unaffected in AD (Figure 3.4). These 
effects were restricted to tau pathology as diffuse and neuritic plaque counts were no 
different between AD and diabetic AD cases. 
In chapter four, we presented evidence that suggests leptin resistance induced 
obesity and diabetes may influence the development of neurodegenerative disease. The 
initial phases of this project began with a high-fat diet study in APP/PS1 mice. Neither 
ketogenic diet nor high-fat western diet resulted in increased amyloid pathology. 
However, this study did reveal that total Aβ levels were negatively correlated with 
plasma leptin levels (Figure 4.1). To further investigate this finding, overexpressing 
human APP in H4 neuroglioma cells were treated with leptin, and we observed a dose 
dependent decrease in Aβ generation related to leptin concentration (Figure 4.2). This 
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reduction in Aβ generation is due to a reduction in γ-secretase expression. The first sign 
of this reduced γ-secretase expression was found in an APP western blot which showed 
that leptin treated cells accumulated α-CTFs. RT-qPCR analysis revealed that mRNA 
levels of all γ-secretase subunits was reduced in cells treated with leptin (Figure 4.3). 
Interestingly, BACE1 expression was not altered by leptin treatment, but BACE2 
expression was increased.  
Leptin is an adipokine which signals satiety and increased energy metabolism via 
the hypothalamus. However, a chronically high level of circulating leptin results in 
desensitization of the hypothalamus to leptin signaling, resulting in leptin resistance. This 
condition is common in obesity and T2DM. To explore the impact leptin resistance may 
have on amyloid pathology, we crossed leptin-resistant db mice with the APP/PS1 (AD) 
line. This line developed obesity and diabetes as a result of leptin resistance (Figure 4.4) 
and MWM testing revealed that db/AD mice develop severe cognitive impairment 
(Figure 4.5). Interestingly, we observed no increase in plaque deposition within the 
brains of db/AD mice when compared to AD mice (Figure 4.6). 
To determine how the db/AD mice develop cognitive impairment without 
increased amyloid deposition, we turned to the brain’s vasculature for answers. Using 
vascular corrosion casting to isolate the structure of the brain’s vasculature we were able 
to visualize vascular events within the brain using SEM. While wild type and db 
displayed no vascular abnormalities, AD and db/AD mice presented with varying degrees 
of pathology ranging from small blebbing of vessels to large complex saccular aneurysms 
(Figure 4.7). This finding did not explain, however, why cognitive deficits were only 
observed in db/AD mice and not AD mice, as they had the same vascular pathology by 
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SEM analysis. Following up this experiment with small animal MRI revealed that db/AD 
mice developed ischemic strokes, which was supported by histological evidence (Figures 
4.8 and 4.9). These findings suggest that a mechanism unique to the db/AD mouse line 
produces cognitive impairment, not due to amyloid, but from extensive cerebrovascular 
pathology.  
In chapter five, we went beyond amyloid to determine how leptin resistance 
induced obesity and diabetes might affect tau pathology. In db/AD mice we observed a 
significant increase in tau phosphorylation in mice homozygous for the db mutation, 
regardless of the AD genotype (Figure 5.1). To verify this observation in cell culture we 
treated HEK293 cells expressing tau mutant P301L with varying concentrations of leptin. 
We observed a significant reduction in tau phosphorylation (Figure 5.2), indicating that 
leptin signaling reduces tau phosphorylation, and the observations in db/AD mice in 
which leptin resistance resulted in increased tau phosphorylation. To further explore these 
mechanisms we created a mouse model of tauopathy and leptin resistance.  
Instead of crossing the Lepr
db/db
 line with a tau transgenic line, as we did in the 
db/AD line in regards to amyloidogenic mutations, we utilized AAV technology to 
introduce the tau mutant P301L into the brains of Lepr
db/db
 mice. Mice with the Lepr
db/db
 
mutation displayed significant increases in weight gain and impaired glucose handling 
(Figure 5.3). AAV tau
P301L
 injected Lepr
db/db
 mice display significantly elevated levels of 
phosphorylated tau (Figure 5.4) compared to other genotypes also transduced with 
tau
P301L
. We demonstrated that AAV tau
P301L
 injected Lepr
db/db
 mice develop significantly 
more tangle pathology within the hippocampus (Figure 5.6). In addition, AAV tau
P301L
 
transduced brains displayed a large number of astrocytic tangles, verified by fluorescent 
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co-labeling for PHF-1 and GFAP (Figure 5.7). Though these astrocytic tangles were 
observed in many brains, their presence was not consistent enough to draw any 
conclusions and is likely a result of variable viral transduction efficiency. Finally, these 
mice did not display any cognitive deficits, despite extensive tangle pathology in all 
genotypes (Figure 5.8). It is likely that the mice had not reached an appropriately 
advanced age for pathology to initiate any cognitive deficit. 
To determine potential underlying mechanisms involved in this acceleration of tau 
pathology in Lepr
db/db
 mice we used western blot to determine if key enzymes known to 
be involved in tau phosphorylation were activated or inhibited. We determined inhibitory 
phosphorylation of GSK3β at serine 9 was significantly reduced in Leprdb/db mice (Figure 
5.9). Additionally, activation of AMPK by phosphorylation at threonine 172 was 
significantly elevated in Lepr
db/db
 mice. AKT and MAPK, however, showed no 
significant alterations in activation by phosphorylation. 
Interestingly, observations from chapter 5 were different than what we observed 
from human case data from chapter 3. Based upon data observed in the db/tau
P301L
 mouse 
model we would have expected NFT counts to be elevated in diabetic AD cases 
compared to AD cases. However, diabetic AD cases displayed significant reduction in 
NFT counts compared to AD cases (Figure 3.4). We suspect that these differences are a 
result of diabetic therapeutics taken by all the human diabetic cases. It is possible that 
diabetes medications counter the effects of diabetes and inhibit the development of 
pathology.  
The ultimate goal of this project was to discern whether or not leptin and leptin 
resistance induced obesity and diabetes might play a role in the development of 
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neurodegenerative disease. Collectively, these results indicate that this metabolic 
dysfunction does indeed play a role in the development of pathology, in relation to both 
amyloidogenic models and tau models of disease, though with very different outcomes. 
Leptin resistance induced obesity and diabetes generate vascular pathology in an 
amyloidogenic model of neurodegenerative disease while tau pathology is exacerbated by 
metabolic dysfunction. Despite many interesting observations, the etiology of 
pathogenesis remains unclear and warrants further investigation.  
6.2 – CONCLUSIONS and FUTURE DIRECTIONS 
 Here we have created new models of leptin resistance induced obesity and 
diabetes with either amyloid or tau pathology. The db model expressing amyloidogenic 
mutations, surprisingly, does not generate more amyloid pathology, but presented with 
cerebrovascular pathology. The db model expressing tau
P301L
 developed increased tau 
phosphorylation and NFT pathology. While these two models provide exciting new 
evidence, suggesting that metabolic dysfunction can result in neurodegenerative disease, 
we are left with more questions than answers.  
 One key drawback to this model is that whole body leptin resistance initiates a 
cascade of events which results in severe metabolic disease, disrupting many systems in 
the brain. To better explore our original hypothesis, that leptin resistance alone might 
promote pathology, we need to develop a better model where leptin resistance is found in 
all regions of the brain, except for the hypothalamus. This would prevent the 
development of obesity and diabetes, while still allowing leptin resistance to influence 
the development of pathology in areas like the hippocampus and cortex.  
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 There are several such ways a modified model could be created. Perhaps the most 
direct model would be to stereotaxically reintroduce the full length leptin receptor into 
the hypothalamus of newborn Lepr
db/db
 pups using an adeno-associated virus. This would 
restore normal leptin signaling along the metabolic axis, but retain leptin resistance in 
other areas of the brain. With this model the only influence on pathogenesis would be 
leptin resistance, and any factors associated with obesity and diabetes we detected in the 
other models would be removed. Unfortunately, the impact of the leptin resistance in the 
prenatal pups may still play a role in pathogenesis. At this point we have no evidence that 
epigenetic or physiological factors associated with leptin resistance in utero may play a 
role in pathogenesis, but more evidence is needed before any conclusions may be drawn.  
 Another option would be to utilize a Lepr flox line in combination with the AD 
line or AAV tau
P301L
 models. Leptin resistance could be induced in specific areas of the 
brain by using an AAV Cre recombinase vector to remove the Lepr gene. This method 
would also allow us to initiate leptin resistance at different ages in mice, to study the 
effects it may have in different stages of amyloid or tau pathogenesis. This model could 
also be beneficial in that normal breeding paradigms associated with breeding the Lepr
db
 
line could be avoided (only heterozygotes may be bred together, and only a quarter of the 
offspring are homozygous for the db mutation).  
Another factor to consider is the signaling effects of different leptin receptor 
isoforms. Multiple leptin receptor isoforms have been identified and are differentially 
expressed throughout the brain (Guan, Hess et al. 1997). While only the long form of the 
leptin receptor has been shown to initiate intracellular signaling events, the function of 
other isoforms is largely unknown (Wang, Zhou et al. 1996, Bjorbaek, Uotani et al. 
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1997). By knocking-out endogenous leptin signaling, then restoring individual isoforms 
in cell culture we could explore the effects of leptin signaling through each isoform and 
determine how Aβ production and/or tau phosphorylation are impacted by each type.  
Aside from isolating the effects of leptin signaling on pathology, there are several 
other avenues that can be investigated to better understand the pathogenic mechanisms 
observed in our disease models. Over time these Lepr
db/db
 mice become gradually more 
insensitive to insulin and develop severe impairment in glucose handling, all of which are 
characteristics of T2DM. Most human T2DM patients with access to healthcare take 
measures to control their disease, including exercise, diet, and pharmaceutical 
interventions. Our current model, however, represents an untreated form of diabetes.  
We briefly ran a controlled exercise trial, where mice were loaded into small 
wheels on a mechanized platform and were forced to run at a certain speed for a specific 
period of time. This brief trial revealed Lepr
db/db
 mice are too obese to perform this basic 
trial, even at an extremely slow speed of one meter per minute. Because of this we ended 
the trial after only a few weeks to avoid any adverse events. Despite the short duration of 
exercise intervention, GTTs completed after the exercise trial ended showed that 
exercised mice had better glucose handling when compared to baseline GTTs performed 
prior to the exercise trial. It was surprising to see such a stark effect with such a short and 
mild treatment.  
To expand on these studies we need to develop a better exercise paradigm in 
which the Lepr
db/db
 mice can perform the exercise over a longer period of time. During 
the initial exercise trial the youngest Lepr
db/db
 mice were four months old, and the oldest 
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were over seven months. By this stage, mice are severely obese (weighing between 65 
and 80 grams) and have difficulty even moving around their cages. By weaning Lepr
db/db
 
mice weigh roughly 25 to 30 grams. This may be a much more reasonable age to begin 
mice on an exercise regimen. Perhaps by starting mice at this age we can attenuate weight 
gain, and inhibit the development or reduce the severity of the diabetic phenotype 
(Figure 6.2).  
Forced exercise is not our only avenue of treatment. Previous studies have used 
swim training to restrict weight gain. Two hours a day for six weeks significantly reduces 
weight of Lepr
db/db
 animals by 15 to 20 percent (Oh, Kim et al. 2007). By utilizing this 
same exercise paradigm over the lifespan of these mice we should be able to restrict 
weight gain, eliminate or reduce the effects of diabetes, and perhaps better understand 
how pathogenesis can be attenuated.  
There have always been two traditional avenues of treating obesity and diabetes. 
In addition to exercise, dietary modifications are commonly prescribed by physicians to 
diabetic patients. The obesity and diabetic phenotypes associated with the Lepr
db/db
 mice 
could be completely removed by caloric restriction. An experiment of this nature would 
provide interesting insights into this model. For one, we could determine how obesity and 
diabetes influence the development of pathology based on which aspects of pathology are 
removed when compared to untreated Lepr
db/db
/AD or Lepr
db/db
/tau
P301L
 mice. Similarly, 
we could determine how leptin resistance may influence the development of pathology.  
Despite the fact that a healthy diet and moderate exercise have always been 
known to be beneficial, funding agencies are looking for more pharmaceutical therapy 
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driven studies. It may be more feasible to use pharmaceutical interventions to treat the 
metabolic dysfunction observed in Lepr
db/db
 mice. Treating these mice with common 
diabetes medications, like insulin, metformin, glipizide, or pioglitazone could provide 
better insights into what we see in the human condition. Most human diabetic patients are 
on several medications to control their blood glucose levels, and by treating Lepr
db/db
 
mice with the same medications we will have a better model of the current human disease 
state. We showed that diabetic AD patients display significantly less tangle pathology 
than non-diabetic AD patients (Figure 3.4). If we can show similar reductions in 
pathology in Lepr
db/db
 mice by treating with diabetic therapies, then we may find new 
ways to use the medications in treating non-diabetic AD patients (Figure 6.2). 
Throughout the 20
th
 century, T2DM became and increasingly common concern 
and in the last 25 years has risen to epidemic levels (Amos, McCarty et al. 1997, King, 
Aubert et al. 1998). The industrial revolution led to some of the greatest changes in 
lifestyles seen throughout all of human history. Decreased necessity for manual labor, 
increased ease of transportation and communication, an ever abundant and increasingly 
processed and preservative-containing food supply, and better medical treatment which 
have all culminated in better long lives. These benefits, however, also have their 
downsides. We’ve become a society of excess, and this has resulted in increased disease. 
The studies presented in this dissertation aid in advancing our understanding of these 
diseases and how they are connected. By building upon these findings, we may uncover 
potential therapeutics to treat neurodegenerative disease associated with metabolic 
dysfunction.  
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Figure 6.1 Model of Leptin Signaling with Amyloid and Tau Pathology. 
In this general model, leptin signaling directly influences the development of pathological 
changes associated with AD. Leptin initiates JAK/STAT signaling pathways which 
inhibit the expression of γ-secretase complex proteins, therefore reducing APP processing 
and Aβ generation. Additionally, leptin signaling inhibits the phosphorylation of tau, 
likely through enzymatic pathways inhibiting tau kinases or activating tau phosphatases. 
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Figure 6.2 Model of Leptin Resistance Induced Pathology and Future Interventions. 
 This model outlines the mechanisms involved in leptin resistance induced obesity and 
diabetes and associated neuropathological development. Leptin resistance induces obesity 
and diabetes. These factors drive an increase in tau phosphorylation and NFT formation, 
in addition to cerebrovascular pathology. By intervening with diet, exercise of 
pharmaceutical therapies we should be able to alter the pathogenesis of these features and 
better understand mechanisms underlying their development.  
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APPENDIX 1: List of Abbreviations 
AAV    Adeno-associated virus 
AD    Alzheimer’s disease 
APP    Amyloid Precursor Protein 
APPswe   APP Swedish mutation (ΔNL) 
AICD    APP intracellular domain 
APOE    Apolipoprotein E 
Aβ    Amyloid-beta 
BACE(1/2)   β-site APP cleaving enzyme (1/2) 
BCA    Bicinchoninic acid 
BIN1    Bridging integrator 1 
BME    β-mercaptoethanol 
BSA    Bovine serum albumin 
CNBP    Cellular Nucleic Acid Binding Protein 
DM1    Myotonic Dystrophy type 1 
DM2    Myotonic Dystrophy type 2 
DMEM   Dulbecco’s modified eagle medium 
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APPENDIX ONE continued 
DMPK    Protein Kinase 
DTT    Dithiolthreitol 
EDTA    Ethylenediaminetetraacetic acid 
ELISA   Enzyme-linked immunosorbent assay 
FBS    Fetal bovine serum 
FTD    Frontotemporal dementia 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
HRP    Horseradish peroxidase 
IPTG    Isopropylthio-β-galactoside 
MAPT   Microtubule associate protein tau 
MEM    Minimum essential medium 
MCI    Mild cognitive impairment 
MMSE   Mini-mental state examination 
MOI    Multiplicity of infection 
MOPS   3-(N-morpholino)propanesulfonic acid 
mRNA   Messenger RNA 
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APPENDIX ONE continued 
NFT    Neurofibrillary Tangle 
PAGE    Polyacrylamide gel electrophoresis 
PCR   Polymerase chain reaction 
PHF   Paired Helical Filament 
PMI    Postmortem interval 
qPCR   Quantitative real-time PCR 
RIPA    Radioimmunoprecipitation assay 
RNA    Ribonucleic acid 
RT-PCR   Reverse transcription PCR 
sAPP(α/β)   Soluble APP (α/β) 
SDS    Sodium dodecyl sulfate 
SMTG   Superior middle temporal gyri 
TBS    Tris-buffered saline 
TBST    Tris-buffered saline (+ Tween) 
ZNF9    Zinc-finger protein 9 
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Symbols 
α    Alpha α 
β    Beta β 
γ    Gamma γ 
μ    Mu μ 
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